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Clinical and Experimental Sepsis 
Review of clinical and experimental sepsis 
            Sepsis, caused by gram-negative (G-) and gram-positive (G+) bacteria, fungi, 
viruses, and parasites has become increasingly significant over the past decades, as it 
affects approximately 700,000 people annually and accounts for about 210,000 deaths per 
year in the US (1-5).  Despite technical developments in intensive care units (ICUs) and 
advanced supportive treatment, the incidence of sepsis is rising at rates between 1.5% and 
8% per year (4, 5).  These rates may be caused by the increased usage of catheters and 
other invasive instruments, chemotherapy for cancer patients, and immunosuppression in 
patients with organ transplants or inflammatory diseases.  Sepsis represents a major 
burden to the US health care system, with costs of approximately $16.7 billion per year, 
due in part to the extended hospitalization of septic patients (4).  Interestingly, the 
contribution of G+ bacteria to sepsis has dramatically increased during the past thirty 
years (5), with Staphylococcus aureus and S. epidermidis being responsible for more than 
half of these cases of sepsis (6, 7).  In addition, the rate of fungal infections is reported to 
have increased more than 200% (5).  The clinical definition of sepsis has been 




Table 1.1 Sepsis diagnostic criteria 
 
General changes     Hyperthermia (> 38.3°C) or hypothermia (< 36°C)   
 Heart rate > 90/min or > 2 SD above normal value for age) 
                                                  Breath rate > 30/min) 
                                                  Changes in mental state 
                                                  Edema or positive fluid balance (> 20ml/kg over 24 h) 
                                                  Plasma glucose > 120mg/dl or > 7.7 mM 
 
Inflammatory changes              WBC > 12×109/L or < 4×109/L 
                                                  Normal WBC count with > 10% immature band forms 
                                                  Plasma C reactive protein > 2 SD above normal 
                                                  Plasma procalcitonin > 2 SD above normal 
 
Hemodynamic changes             Arterial hypotension (SBP < 90 mmHg, MAP < 70, or a SBP decrease > 40    
                                                  in adults or < 2 SD below the normal for age) 
                                                  SvO2 > 70% 
                                                  Cardiac index > 3.5 L/min/M-23 
 
Organ dysfunction                    Arterial hypoxemia (PaO2/FiO2 < 300) 
                                                  Acute oliguria (urine output < 0.5 ml/kg/h or < 45 mM for at least 2 h) 
                                                  Creatinine increase > 0.5 mg/dl 
                                                  Coagulation abnormalities (INR > 1.5 or aPPT > 60 s) 
                                                  Ileus (absent bowel sounds) 
                                                  Platelet count < 100,000/µL 
                                                  Plasma total bilirubin > 4 mg/dl or > 70 mM  
 
Tissue perfusion                       Serum lactate level > 1mM 
                                                  Decreased capillary refill                                
 
 
WBC, white blood cell; SBP, systolic blood pressure; MAP, mean arterial pressure; SvO2, mixed venous 
oxygen saturation; PaO2, arterial partial pressure of oxygen; FiO2, fraction of inspired oxygen; INR, 
international normalized ratio; aPPT, activated partial thromboplastin time. 
 
Discussion at the most recent consensus conference led to the establishment of the 
extended definition of sepsis, which is outlined in table 1.1 (8-10).  
            During the initiation and progression of sepsis, two dynamic stages are present; a 
systemic inflammatory response syndrome (SIRS) in the acute phase and a compensatory 
anti-inflammatory response syndrome (CARS) in the later phase (9).  The hallmark of 
SIRS/CARS is an exacerbated production of pro-and anti-inflammatory 
cytokines/chemokines, leading to the so-called “cytokine storm”.  While these 
inflammatory mediators are essential in providing an effective host defense, their 
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overzealous production can be deleterious, resulting in a “double-edge sword” property 
of reducing pathogens at the expense of organ injury (11, 12).  In the host, toll-like 
receptors (TLRs) and intracellular pattern recognition receptors (PRRs) [e.g. nucleotide-
binding oligomerization domain (NOD)-leuine-rich repeat (LRR) family (NOD-LRR)] 
act as sensors for invading pathogens or their components, resulting in the release of an 
array of proinflammatory mediators from both leukocytes and structural cells.  These 
mediators include, but are not limited to, tumor necrosis factor (TNF)-α, interleukin (IL)-
1β, IL-6, CXCL8 (IL-8), IL-18, CCL2 (MCP-1), CCL3 (MIP-1α), CXCL10 (IP-10) (10, 
11, 13, 14), prostaglandins, lipid mediators and reactive oxygen species (7).  The effects 
of these host-derived factors include vasodilatation and upregulation of adhesion 
molecules, resulting in the extravasation of leukocytes and the activation of these cells 
along with epithelial and endothelial cells.  Coagulation is an additional vascular event 
that is dictated directly by pathogen components and indirectly by pathogen-induced 
cytokines.  This physiological response can be more severe and result in disseminated 
intravascular coagulation (DIC), causing hypoperfusion, hypoxia and death.  Collectively, 
the tissue damage caused by activated immune cells and pathological coagulation 
resulting in DIC can lead to multiple organ failure (MOF), involving the lungs (acute 
respiratory distress syndrome), liver, and kidneys (2, 15-17).  Based on the understanding 
of molecular mechanisms underlying sepsis, new clinical therapies have been designed to 
neutralize several key molecules involved in the initiation and progression of sepsis, 
including lipopolysaccharide (LPS), a core component of G- bacteria cell wall, IL-1 and 
TNF-α.  Although experimental studies using animal models of sepsis has documented a 
beneficial effect of these therapies (18-22), subsequent clinical trials were disappointing 
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as they showed no substantial benefits (23-27).  So far, recombinant human activated 
protein C that targets coagulation remains the only effective new therapy for clinical 
severe sepsis (28).  These observations support the concept that severe sepsis is a highly 
dynamic and complex disorder and efficient treatment strategies remain elusive.             
            In order to understand the mechanisms of clinical sepsis and develop effective 
therapeutic modalities, there is a need to use effective experimental models that faithfully 
replicate what occurs in patients with sepsis.  Several models, including intravenous 
endotoxin challenge, injection of live organisms into the peritoneal cavity, establishment 
of abscesses in the extremities, and the induction of polymicrobial peritonitis via cecal 
ligation and puncture (CLP) have been used to study sepsis (29-31).  The latter 
experimental model, CLP, has been proposed to more closely replicate the nature and 
course of clinical sepsis, as compared to other models (32, 33).  The benefits of the CLP 
model are its reproducibility and the potential to alter the severity of sepsis by controlling 
needle size, number of cecal punctures and antibiotics utilization (34).  The following 
surgical conditions have been successfully utilized to induce severe sepsis in mice: a 21G 
needle was used to puncture the cecum 9 times, followed by antibiotics treatment and 
saline resuscitation for 3 days.  The genetic background of the animals is also important.  
In contrast to T helper (Th) 2-dominant BALB/c mice, C57BL/6 mice are Th1-dominant 
and more resistant to trauma-induced sepsis (35) and Th1-eliciting pathological infections, 
such as Leishmania major (36, 37).  Thus, female C57BL/6 mice were used extensively 
as an animal of choice for inducing experimental sepsis.  On average, this nine-puncture 
CLP procedure results in approximately 40% mortality in the acute phase of sepsis (38-
40).  Following the induction of CLP-induced peritonitis, inflammatory cytokines/ 
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chemokines such as IL-12p70, IL-10, TNF-α, CCL2, CCL3 and CXCL10 are rapidly 
induced in the peritoneal cavity (local response) (Fig 1.1A), blood (Fig 1.1B) and 
peripheral organs (systemic response) (data not shown) within 4 hours and peak at 24 
hours.  Three days later, the local and systemic levels of inflammatory 
cytokines/chemokines mostly return to baseline levels, indicating the end of the acute 




Figure 1.1 Cytokine profile 
following experimental 
peritonitis.  At different 
time point (4, 24 and 72 
hours) after cecal ligation 
and puncture (CLP) 
procedure, peritoneal lavage 
fluid (A) and blood samples 
(B) were collected.  Levels 
of inflammatory cytokines 







Long-term immunosuppression following sepsis 
            A high mortality rate is often found during the acute phase of severe clinical 
sepsis, which may be associated with the development of a sustained anti-inflammatory 
IL-12p70


































































































or immunosuppressive state.  This response has been termed “immunoparalysis” and 
often follows the initial hyper-inflammatory response.  The immunoparalysis is 
manifested by an inability to eradicate a primary infection and/or the development of new 
secondary infections (41-46).  Many of the pathogens responsible for the secondary, 
hospital-acquired infections are not particularly pathological in patients with competent 
immune systems, indicating the immunosuppressive state of patients with sepsis.  
Interestingly, this particular population of septic patients is at significant risk of dying 
from various complications up to 8 years after initially being hospitalized for sepsis (47, 
48).  Thus, the original episode of severe sepsis, characterized by a dysregulated 
inflammatory response, appears to lead to long-lasting host defense complications.  
            Although the mechanism(s) that is responsible for severe sepsis-induced long-
term immunosuppression is still under investigation, it has been proposed that depletion 
of immune cells via apoptosis following sepsis is an initiating factor involved in this 
process (49, 50).  In patients who die of sepsis, extensive apoptosis of lymphocytes and 
gastrointestinal epithelial cells have been observed, as compared with patients who die of 
non-septic etiologies (49).  Further studies revealed that most of the apoptotic 
lymphocytes are B cells and CD4+ T cells (51) with a significant loss of circulating 
lymphocytes in septic patients compared with non-septic patients in the ICU (52, 53).  In 
addition, dendritic cells (DCs) are essential immune cells that are reported to be 
dramatically depleted in septic patients (54).  Similar observations have been made in 
experimental animal models of sepsis, which have documented significant apoptosis of 
lymphocytes and DCs (55-59).  We have monitored the presence of CD11c+CD11b+ 
MHCIIhi myeloid DCs (mDCs) in both lung and spleen at different time points following 
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the induction of experimental CLP-induced peritonitis.  At early time points after CLP, 
myeloid DCs were significantly decreased in both the lungs and spleens from septic mice 
compared with sham control, which is consistent with the above studies.  The proportion 
of splenic and lung mDCs gradually returned to the levels found in sham mice 4 weeks 
and 10 weeks after CLP, respectively (Fig 1.2).  CD11c+B220+ plasmacytoid DCs (pDCs), 
another subset of DCs, showed a similar dynamics after severe sepsis-initial depletion 
followed by gradual recovery (data not shown).  Thus, severe sepsis causes the depletion 
of DCs, the most potent antigen-presenting cells (APCs), which compromises both the 
innate and adaptive immune response.  The profound decrease in the numbers of T and B 

















* * * *




Figure 1.2 Alteration in DC percentages in spleen and lung following experimental 
peritonitis.  At different time point after cecal ligation and puncture (CLP) procedure, 
spleen (A) and lung (B) were collected and dispersed.  The cells were stained with FITC-
anti-CD11c, PerCP-Cy5.5-anti-CD11b and PE-anti-I-Ab.  Myeloid dendritic cells (mDCs) 
were characterized as CD11c+CD11b+MHCIIhi.  *, p <0.05 compared with mDC numbers 
observed in sham mice. 
             
            Based on the long-term susceptibility of septic patients to secondary pathological 
infections (48), and our observation of a gradual restoration of DCs after severe sepsis 
(Fig 1.2), it is likely that immune cell depletion alone is not the only mechanism 
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responsible for the long-term immunosuppression found in post-septic patients and 
animals.  Dysfunction of re-established immune cells may be another potentially 
important mechanism.  However, It is worth noting that the apoptosis and dysfunction of 
immune cells are not exclusive to each other.  It has been reported that apoptotic cells 
induce anergy and Th2 response in surviving immune cells (50, 60, 61), promote the 
production of anti-inflammatory cytokines by DCs and macrophage (62), and inhibit the 
release of pro-inflammatory cytokines (63, 64).  While convincing data have identified 
sepsis-induced depletion of immune cells as a mechanism leading to sepsis-induced 
immunosuppression, few investigations have focused on alteration in immune cell 
function after immune cells have been restored to depleted tissues.  Previously, using 9-
puncture CLP procedure, our group has characterized the immunosuppressed status of the 
survivors of severe experimental sepsis.  These post-septic mice were susceptible to a 
pulmonary challenge of Aspergillus fumigatus, a relatively innocuous microbe, compared 
with sham mice (38, 46).  This study highlighted an impaired innate pulmonary immune 
response in post-septic mice, since A. fumigatus normally poses few problems to an intact 
pulmonary immune system.  Furthermore, adoptive transfer of bone marrow-derived DCs 
(BMDC) from sham mice restored the protective immune response of post-septic mice to 
A. fumigatus challenge.  This observation, together with the consideration of the essential 
role of DC in both innate and adaptive immunity, led us to hypothesize that severe sepsis-
induced DC dysfunction is an important mechanism of long-term immunosuppression 
after the acute phase of sepsis.   
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Dendritic cell biology 
Dendritic cell subtypes and precursors 
            The DCs were first described by Ralph Steinman as a novel cell population in the 
mouse spleen (65-67).  Since then, the properties and functions of this unique immune 
cell have been extensively studied. DCs comprise a heterogeneous group of cells with 
particular locations and divergent effects on the immune response (68, 69).  Traditionally, 
DCs are categorized according to the expression of a series of surface markers, which 
differ in such immune functions as cytokine production, antigen uptake and presentation 
(Table 1.2) (70, 71).  At least six subtypes of DCs under steady state have been 
characterized (68, 72), and their individual properties are briefly summarized in table 1.2. 
It is interesting to note that novel DC populations that are not found in the steady state 
have been characterized as a consequence of infection or inflammation (69).  Several 
studies have reported the existence of these inflammatory DCs; namely tumor necrosis 
factor and inducible nitric oxide synthase-producing DCs (Tip DCs), DCs produced in 
vivo when pDCs are stimulated by the influenza virus (73) and DCs that appear after 
challenging mice with either Listeria monocytogenes (74) or Leishmania major (75).  
            DCs originate as haematopoietic stem cells (HSCs) in the bone marrow (BM) 
giving rise to a series of downstream precursor cells, including the common myeloid 
progenitor and the common lymphoid progenitor (76, 77).  Although it was initially 
considered that DCs solely originated from myeloid-lineage precursors, subsequent 
studies revealed that both myeloid and lymphoid precursor cells can generate DC 
subtypes (77-82).  A study using limiting-dilution approach has shown that both a single 
common myeloid progenitor and a single common lymphoid progenitor could generate 
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Table 1.2 Murine DC subsets and important properties 
 
              Conventional DC        Plasmacytoid DC 
 
Surface markers     CD8+ DC   CD4+ DC   DN DC   Langerhans’ cell   Dermal DC  
     
   CD11c                       +                 +               +                  +                          +                        Low 
   MHCII                       + 
   CD8α                        +  - - -/low -  ±  
   CD4                           -  + - - -  ±  
   CD205                       + -    -   High +                         -  
   CD11b -  +    +   + ±    - 
   CD45RA   -      -    -    -                          -   + 
IL-12 production  +       ±    ±    ?  ?    - 
IFN-γ production  +       -    -   ?  ?    - 
IFN-α production  -      -    -   ?  ?  high 
Ag-presenting   +      +   +   + +   ?  
CD4 T-cell  +      +   +   + +   + 
  priming 
 
DN, double negative;  
  
both conventional DCs (cDCs) and pDCs (81).  These observations imply the 
developmental flexibility of DC lineages at the early precursor stage.  Thus, it seems to 
be more appropriate to ask which early precursor population contributes to DC generation 
in vivo, instead of asking which population, either myeloid or lymphoid precursor cells, 
has DC developmental potential in an in vitro assay system (69).  Since myeloid 
precursors are numerically dominant in BM, it is possible that most DCs in peripheral 
sites and the secondary lymphoid organs such as the spleen or lymph nodes should be of 
myeloid origin, whereas in the thymus, where lymphoid precursors are dominant, most 
DCs may be of lymphoid origin.  The extent to which these precursors contribute to DC 
commitment needs further investigation (69).  Interestingly, several studies revealed a 
common progenitor population for DCs and macrophage (83, 84).  These CX3CR1+c-
kit+Lin- clonogenic precursor cells identified in the bone marrow (BM) could give rise to 
DCs and macrophages, but not polymorphonuclear cells (PMNs), B or NK cells (84).  
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Furthermore, CX3CR1+c-kit+Lin- cells exist within the c-kit+ Sca1-IL-7Rα- CMPs 
populations (77), indicating that the crucial events in DC differentiation and the 
development of the separate DC subtypes are downstream of CLPs and CMPs (69).  
            In addition to the complexity and controversy of the commitment and 
development of DCs under steady state, it has been well characterized that inflammatory 
CCR2+ blood monocytes can differentiate into DCs under conditions of inflammation (75, 
85-87).  The differences between monocyte-derived inflammatory DCs and steady-state 
splenic cDCs include the expression levels of CD11c, CD11b, MAC3 (a glycoprotein 
also found on activated macrophages) and the presence or absence of CD4 or CD8 
expression (69, 88).  Since these inflammatory DCs are absent under steady state (75, 85, 
88), they are considered to be transient cells of an inflammatory response and further 
highlight the developmental flexibility of DCs under steady state.    
Role of Dendritic cells in innate and adaptive immune response 
            DCs are unique immune cells in that they function in both the innate and the 
adaptive immune response and bridge these two branches of host immunity (72, 89-91). 
In the innate immune response, DCs recognize pathogen-associated molecular patterns 
(PAMPs) via the functions of a series of germ-line-encoded receptors known as pattern 
recognition receptors (PRR), including DEC-205, the mannose receptor, the scavenger 
receptors and toll-like receptors (TLR) (92, 93).  
            TLR family are the best-characterized class of PRR molecules and are localized 
either on the cell surface (TLRs 1, 2, 4, 5, 6) or in intracellular compartments (TLRs 3, 7, 
8, 9), detecting a multitude of PAMPs from a wide variety of pathogens (94, 95).  For 
example, TLR4 in complex with myeloid differentiation protein-2 (MD-2), an accessory 
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Table 1.3 TLR expressions on Murine DC subsets and signaling pathways 
  DC subtypes          MyD88                     MyD88 
                               CD8+ DC    CD4+ DC    DN DC    pDC  dependent                independent 
     
   TLR1a                        +                +                 +            +                                                 
   TLR2                         +  + + + + - 
   TLR3                         +  +  +           +      - + 
   TLR4                         +  +  +           +  +   + 
   TLR5                         +  -     +           +  +  - 
   TLR6 a                       +                 +     +           +        
   TLR7  +      -     +           +                        +      - 
   TLR8  +       +     +           +  +     - 
   TLR9 +       +     +           +    +  - 
   MyD88, myeloid differential factor 88; a Either TLR1 or TLR6 functions in a complex with TLR2.  
 
protein, recognizes LPS from G- bacteria (96, 97); TLR2 detects peptidoglycans (PGN) 
from G+ bacteria (98); TLR3 recognizes double-stranded RNA (dsRNA) from double-
stranded and negative-strand viruses (99); TLR 7 and 8 recognize single-strand viral 
RNA (100, 101); TLR9 detects unmethylated CpG motifs present in viral and bacterial 
DNA (102, 103); TLR5 detects bacterial flagellins (104); TLR11 detects protozoan 
profilin-like proteins (105).  In addition to ligand specificity, individual TLRs differ in 
their expression patterns on DC subtypes and the signal transduction pathways they utilite, 
including myeloid differentiation factor 88 (MyD88)-dependent or –independent 
pathways (Table 1.3) (106).  The activation of DCs via TLRs plays a pivotal role in 
shaping the outcome of primary immune responses.  This is due to the multiple functions 
of DCs, including their ability to generate numerous cytokines and chemokines, enhanced 
phagocytosis and killing of invading microbes, regulation of recruitment of the 
inflammatory immune cells, activation of both leukocytes (NK cells, mast cells) and 
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stromal cells (92, 106, 107) and the inhibition of anti-inflammatory function of regulatory 
T cells (Treg) (108).  
            Besides its important role in innate immunity, DCs are the most potent antigen-
presenting cells (APC) and responsible for the initiation of adaptive immune responses 
(72, 89).  In the peripheral tissues, DCs take up antigens and process them into optimal 
peptides in lysosomes (109, 110).  The engagement of TLRs with their appropriate 
ligands activate and induce DC migration to draining lymphoid tissues to present these 
antigenic peptides on the relevant major histocompatibility complex (MHC) molecules.  
The entire process involves phagocytosis and processing of antigen, the upregulation of 
costimulatory and MHC molecules, a switch in chemokine receptor expression, the 
secretion of cytokines and chemokines, and the presentation of antigens by DCs to T-cell 
receptor (TCR) specific naïve T cells (72, 106).  The activated T cells undergo an initial 
clonal expansion that generates effector T-cells, followed by clonal contraction.  Finally, 
memory T cells are generated and maintained for an extended period (111, 112). 
Depending on the properties of antigens, expression of costimulatory molecules on DCs 
and T cells, and the cytokine environment, the so-called “3 signals” (113), diverse Th1, 
Th2, Th17 and Treg responses can be induced to defend the host against a myriad of 
pathogens (114).  DCs play a key role in all of the following lymphocyte-mediated 
responses.  In response to infections with intracellular microbes or viruses, CD4+ T cells 
differentiate into Th1 cells that produce IFN-γ and enhance the killing function of CD8+ 
cytotoxic T cells (CTLs) targeting infected cells.  In contrast, in response to parasite 
infections, Th2 cells are induced and produce Th2 cytokines (IL-4, IL-5, and IL-13), 
induce IgE production by B cells and enhance eosinophil-mediated destruction of the 
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pathogen.  Th17 cells have recently been characterized by the production of IL-17 and 
are key cells to the immunopathology associated with multiple autoimmune diseases 
(115).  Furthermore, bacterial and viral infections promote the generation of Treg and 
enhance their functions, which subsequently suppress the proliferation and differentiation 
of Th or CTLs and limit the potential immunopathology that might be caused by an 
overexuberant immune response (116, 117). 
            One of the inflammatory cytokines generated by activated DCs, IL-12, is 
extremely important to the progression of immune reactivity as this cytokine can induce 
interferon-γ production, direct the differentiation of Th1 cells, and form a link between 
innate and adaptive immune response (118).  IL-12 is a heterodimer composed of a 35-
kDa light chain (p35) and 40-kDa heavy chain (p40) (119), encoded by p35 and p40 gene 
located in different chromosomes both in mouse and human: p35 (human chromosome 3; 
mouse chromosome 3) and p40 (human chromosome 5; mouse chromosome 11).  Thus, 
the efficient production of biologically active IL-12p70 requires the coordinate 
transcription and translation of both genes in the same cell (118, 120).  The upregulation 
of both subunit genes can be induced by external stimuli such as TLR agonists (121).  
The transcriptional factors essential for gene expression are not identical but rather 
overlapping between the two genes (122).  IL-12p70 signals through IL-12 receptor 
composed of two chains IL-12Rβ1 and IL-12Rβ2, which subsequently activate the Janus 
kinase (JAK)–signal transducer and activator of transcription (STAT) signal transduction 
pathway.  STAT4 is especially responsible for IL-12 cellular effects.  
Activated/phosphorylated STAT4 is relocated into nucleus, binds to the promoter regions 
of target genes and initiates IL-12-mediated gene transcription together with other 
 
 15 
essential transcription machinery (123, 124).  Activation of T cells through the TCR 
promotes IL-12R expression on the cell surface and further induces T cell responsiveness 
to IL-12.  IL-12R expression is also induced by IL-12 itself, IFN-α, IFN-γ, TNF-α and 
via co-stimulation through CD28 (125, 126). 
            IL-12 is a pro-inflammatory cytokine in the context of pathological infections and 
is produced by a series of activated inflammatory cells, including DCs, monocytes, 
macrophages, neutrophil and microglia (118).  IL-12 production is controlled by both 
positive and negative mechanisms.  While TLR agonists and IFN-γ are strong inducers of 
IL-12 production, IL-10 and transforming growth factor-β (TGF-β) are potent inhibitors 
of IL-12 production (127-129).  Interestingly, the balance between IL-10 and IL-12 has 
been observed in specific pathological conditions, such as tumors and autoimmune 
diseases, indicating that there might be a reciprocal regulatory mechanism(s) of these two 
important genes (130, 131).  Th1 differentiation and IFN-γ production require the 
presence of IL-12 (132).  Although IL-12 production is not limited to DCs, DC-derived 
IL-12 is essential for the initiation of Th1 immune response against intracellular 
pathogens in vivo, since DCs are the most potent APCs and function to contact and 
activate TCR-specific naïve T cells (72).  IL-12 also enhances the generation and 
functions of CTLs and NK cells in part by inducing the transcription of genes that encode 
cytotoxic granule-associated molecules such as perforin and granzymes and by 
upregulating the expression of adhesion molecules (118).  In summary, DCs are essential 
immune cells for host resistance against infectious agents and DC-derived IL-12 is the 
key cytokine involved in initiating a Th1 immune response.  
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            In addition to TLRs, signals through chemokine/chemokine receptors also 
mediate DC activation and migration both in homeostasis and in pathological conditions 
(133).  Chemokines represent a large superfamily of 8- to 15-kd proteins that possess 
diverse biological functions, such as the maintenance of homeostasis, 
angiogenesis/angiostasis, wound healing, tumor growth and metastasis, cellular 
differentiation and activation, lymphocyte development and trafficking, lymphoid organ 
development, and influencing the type 1/type 2 balance of an immune response (133, 
134).  Chemokines are divided into four different groups based upon a conserved cysteine 
arrangement: CC, CXC, C and CX3C.  Chemokine receptors belong to a large family of 
G protein-coupled receptors (GPCRs) that are characterized by seven-transmembrane 
domains and utilize heterotrimeric G proteins for downstream signal transduction.  The 
promiscuous interactions between chemokines and chemokine receptors complicate their 
roles in the immune system.  Immature and mature DCs express a distinct repertoire of 
chemokine receptors that mediate their migration either into infected peripheral sites 
(inflammatory), or into draining lymph nodes (homing).  Among inflammatory 
chemokine receptors, CCR6 is unique in that it has only one chemokine ligand, 
CCL20/MIP-3α (135).  CCL20 plays a key role for the homing of DC to mucosal 
surfaces, and CCR6/CCL20-dependent immature DC migration is an essential 
mechanism for CD8+ T cell activation and host immunity against invasive pathogens in 
the skin and GI tract (87, 136).  CCR6-/- mice have a defect in both leukocyte 
homeostasis and in the humoral response to an oral antigen challenge (137, 138).  Despite 
an established role of CCL20/CCR6 in adaptive immunity, little is know about their role 
in the innate host response.  
 
 17 
Role of Dendritic cells in granulomatous response 
            Granulomas are specific immune sequestration responses of mononuclear 
phagocytes that function to “wall off” pathogens that cannot be phagocytosed or 
destroyed by surrounding immune cells in order to prevent their dissemination to healthy 
tissue (139).  Thus, the granulomatous response is considered to be a compromised 
strategy of the host to deal with specific pathogens that they fail to completely destroy.  
Granulomatous responses have been characterized in response to different agents, such as 
bacteria, fungi or helminthes that induce immune hypersensitivity granulomas, and other 
agents that induce non-immune foreign-body granulomas.  Hypersensitivity granulomas 
can be further classified as either type-1 or type-2, depending upon whether a 
predominant Th1 or Th2 cytokine immune response.  Examples of Th1 or Th2-type 
granulomas are those induced by tuberculosis and schistosomiasis, respectively. 
            The granulomatous response induced by i.v. administration of live Schistosoma 
mansoni eggs has been well characterized as a cell-mediated, Th2-dominant immune 
response.  This granulomatous response has been accepted as a valuable model to study 
Th2 polarization, the function of individual immune cells that are involved in the 
initiation and development of the granulomas (DCs, monocytes/macrophages, eosinophils, 
lymphocytes, et al), and function of important molecules responsible for cell activation 
and migration (139-142).  Either a single i.v. injection of live S. mansoni eggs (primary 
granuloma), or sensitization of animals with S. mansoni egg antigen (SEA) followed by 
i.v. injection of S. mansoni live eggs (secondary granuloma) can be used to 
experimentally induce granuloma formation in the lung.  In contrast to secondary S. 




Figure 1.3 Primary lung 
granulomas induced by 
Schistosoma mansoni eggs. 
Left panel, 4 days after egg 
injection; middle panel, 8 
days after egg injection; right 
panel, 16 days after egg 
injection.   
 
 
response in the very early time point (day 2) after the induction of primary granulomas, 
i.e. the upregulation of both Th1 cytokine IFN-γ and Th2 cytokines IL-4, IL-5, IL-13 
(143).  As the granulomas develop in response to the stimuli, Th2 cells rapidly dominate 
over Th1 cells, evidenced by the further increase in levels of Th2 cytokines.  In the later 
stage (day 16), eosinophil recruitment and tissue fibrosis are evident in the 
granulomatous lesions, events primarily mediated by IL-5 and IL-13, respectively (144, 
145) (Fig 1.3)    
            As immune cells that link innate and adaptive immunity, DCs have been studied 
in the context of Th1 or Th2 granulomas.  They are recognized as an essential component 
of the granulomas and play a role in both the generation and regulation of the 
granulomatous response (142).  The formation and development of both Th1 and Th2 
granulomas are accompanied by an increase in DC migration and activation, further 
indicating that DCs participate in the granulomatous response (139, 141).  Moreover, 
DCs themselves can be activated and “educated” to possess Th1-inducing capacity in 
response to Th1-eliciting antigens when they are adoptively transferred into recipients 
(139).  Since the ablation of CD11c+ DCs is possible by treating CD11c-diphtheria toxin 
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receptor (DTR)-green fluoresent protein (GFP) transgenic mice with low dose of DT 
(146), it will be of interest to study the granulomatous response in the absence of CD11c+ 
DCs.  Those experiments will offer the direct evidence of the role of DCs on the 
granulomatous response and the effect of DCs on other immune cells that contribute to 
granuloma formation.  
            The activation of DCs by the Th2-inducing antigen SEA is an enigma.  Our group 
and others have observed that in contrast to well-recognized TLR agonists, SEA fails to 
induce the upregulation of DC activation-associated molecules, such as CD40, CD80, 
CD86 and MHCII, and promote the production of several classical pro-inflammatory 
cytokines (H.W. and S.L.K., unpublished data) (147-149).  More importantly, SEA fails 
to promote IL-4 or IL-10 production by DCs.  The classical “DC maturation” model 
states that “immature” DCs, characterized by low expression of MHCII, costimulatory 
molecules (CD80 and CD86) and CD40, are efficient in antigen uptake and processing, 
but poor in T cell priming.  In contrast, “mature” DCs are potent in antigen presentation 
to TCR specific T cells and result in protective immunity (150, 151).  Thus, these 
observations are somewhat conflicting against the classical “DC maturation” model, as 
SEA-stimulated “immature” DCs (low expression of MHCII, costimulatory molecules 
and CD40) proved to be efficient activators of naïve T cells and induce a definitive SEA-
specific Th2 response after transfer into naïve recipient mice (147, 152).  Confounding 
this model is that “mature” DCs are not always immunogenic and have been reported to 
cause T cell depletion, anergy, or regulate and maintain peripheral tolerance in some 
circumstances (153).  The apparent discrepancy suggests that “phenotypically mature” 
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DCs do not necessarily equal “functionally mature” DCs (113); other molecular and 
cellular mechanisms may influence DC: T cell interaction and needs further investigation.       
            IL-12 based vaccination has been shown to attenuate granulomatous response and 
tissue fibrosis induced by S. mansoni eggs, supporting the classical Th1/Th2 paradigm 
(154, 155).  Experiments examining the interactions between DC and pathogens raised 
the possibility that IL-10 may balance IL-12 in deciding between the Th1 and Th2 fate 
(156).  The effects of IL-10 have been associated with the promotion of a Th2 phenotype 
(157) and DC-derived IL-10 can limit Th1 expansion both through its autocrine inhibition 
of IL-12 (158) and by its ability to stimulate IL-10 release from T cells later in the 
immune response (159).  Thus, the granulomatous response induced by S. mansoni eggs 
may be an ideal model to study IL-12/IL-10 balance, as well as DCs functions. 
                           
Epigenetic regulation of gene expression 
General concept of epigenetic mechanism of gene regulation 
            Epigenetics is the study of mitotically and/or meiotically heritable changes in 
gene function that cannot be explained by changes in DNA sequence.  These changes 
include DNA methylation, histone modification, chromatin remodeling, and histone 
variant incorporation (160).  In the last decade, chromatin biologists have achieved 
convincing data suggesting that the regulation of chromatin structure or epigenetic 
regulation confers heritable stabilization of gene expression patterns and thereby plays an 
essential role both in basic physiological processes and in diseases (161, 162).  In 
addition to the interactions between transcription factors (TFs) and DNA sequences in 
promoters and other regulatory regions, gene expression in eukaryotic cells is also 
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influenced by epigenetic changes in chromatin structure that control the access of DNA-
binding proteins, such as TFs and RNA polymerase II, to their conserved binding sites 
during the initiation period of transcription.  Conversely, TFs dictate epigenetic changes 
by recruiting histone-modifying enzymes and chromatin-remodeling complexes. 
            In eukaryotic cells, DNA is packed into a high-order nuclear structure called 
chromatin with the assistance of chromosomal proteins such as histones.  The basic unit 
of chromatin is the nucleosome, which consists of 146 base pairs of double-strand DNA 
wrapped around a histone octamer protein core (two molecules each of H2A, H2B, H3 
and H4) (163, 164).  Histone modifications, including acetylation, phosphorylation, 
methylation, and ubiquitylation, are under intensive investigation and have been 
considered to be an important epigenetic mechanism regulating gene expression.  These 
modifications, catalyzed by several families of histone-modifying enzymes, form a 
“histone code” that constitutes an important epigenetic determinant of the transcriptional 
state (165, 166).  Individual histone modifications can be simply categorized as 
"permissive" or "repressive", in reference to gene transcriptional activity (Table 1.4).  For 
example, histone acetylation is generally associated with gene activation, partially due to 
neutralization of the positive charge of the ε-amino group of lysine and a consequent 
lowered stability of interactions between histones and the negatively charged DNA (167).  
Acetyl histones can also provide a specific binding site for bromodomian-containing 
proteins, such as ATP-dependent chromatin remodeling complexes, which help to 
unravel chromatin structure and recruit essential TFs (168, 169).  Two classes of 
acetylation-modifying enzymes, histone acetyltransferases (HATs) and histone 
deacetylases (HDACs), mediate an increase and decrease in lysine acetylation, 
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Table 1.4 Histone modifications 
 
 Chromatin modifications          Relevant histone sites  Transcriptional role 
  
   Acetylation  H3 (9,14,18,56), H4 (5,8,13,16)           Activation 
   (lysine)                          H2A, H2B 
    
  Methylation  H3 (4,36,79) Activation 
  (lysine)  H3 (9,27), H4 (20) Repression 
    
  Methylation  H3 (17,23), H4 (3) Activation 
  (Arginine) 
  
  Phosphorylation H3 (3,10,28), H2A, H2B Activation 
  (Serine/Theorine)                                                
 
  Ubiquitylation              H2A (119)   Repression 
  (lysine) H2B (123/120) Activation 
 
  Sumoylation  H2A (126), H2B (6/7) Repression 
   (lysine)                           
 
  Isomerization  H3 (30-38)                                            Activation/Repression 
  (Proline)    
    
 
respectively, and the balance between them determines lysine acetylation status.  It is 
worth noting that HATs and HDACs can also regulate gene transcription by modifying 
other non-histone proteins such as BCL6, Runx and p53, and thereby altering their 
stability and/or transcriptional potential (170-174).  Although histone acetylation is an 
essential step during initial gene transcription, it has been suggested that histone 
acetylation is dynamically regulated by HATs and HDACs and is not stable; therefore, 
histone acetylation cannot be inherited to progeny cells (170, 175).  Histone acetylation is 
not likely an initiator of epigenetic changes influencing gene activation, but probably it is 
a responder to other more stable epigenetic changes such as histone methylation.  
            Histone methylation is now recognized as an important modification linked to 
inherited changes in both transcriptional activation and repression (165).  The landmark 
discovery of the molecular identity of the first histone methyltransferase (HMT), 
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SUV39H1, by Jenuwein et al. demonstrates that histone methylation is able to regulate 
RNA synthesis (176).  Histones contain numerous lysine and arginine amino acids and 
can be modified on both of the amino acids with up to three methyl groups.  Methylation 
of lysine residues at six sites (H3K4, -9, -27, -36, -79 and H4K20) has been linked to 
transcriptional regulation (165, 177), which in conjunction with various methylation 
levels (mono-, di- or tri-methylation) provides remarkable regulatory potentials for 
chromatin modification and gene regulation.   
            Lysine methylation is mediated by so-called SET domains, which originally was 
characterized as a common motif in three main classes of HMTs in Drosophila: 
SU(VAR)3-9 (178), the Polycomb-group protein E(Z) (179) and trithorax protein (180).  
They are specifically responsible for the methylation of H3K9, H3K27 and H3K4, 
respectively.  H3K4 methylation (H3K4me) generally correlates with gene activation and 
is therefore considered a permissive modification (Fig 1.4).  H3K4me3 has been found to 
be associated with the promoter and 5’-coding regions of active genes in yeast and higher 
eukaryotes (165, 181).  H3K4me2 exhibits a much broader genomic distribution, 
including transcriptionally active genes, inactive genes that are kept in a transcriptionally 
permissive state, and regulatory elements such as distal enhancers and insulators (182). 
Thus, it seems that H3K4me3 functions specifically in the initiation of gene transcription, 
presumably by maintaining permissive chromatin structure and assisting the recruitment 
of TFs and RNA polymerase machinery.  The first H3K4 methyltransferase to be 
identified was the S. Cerevisias Set1 complex (183).  Mixed-Lineage Leukemia (MLL), a 
mammalian homologue to the Drosophila trithorax protein, is one of the best-




Figure 1.4 Diagram of the biological effects of methylation at histone K3 lysine-4 
(H3K4) and H3K27.  H3K27 methylation maintains the chromatin in a conformation 
that does not allow transcription factors access to a promoter and the gene is silenced. 
When H3K4 is methylated the conformation of the chromatin is relaxed and the 
transcription factors now have access to the promoter, resulting in gene expression.  MLL 
complex containing core components MLL, WDR5, RbBP5 and Ash2L possesses methyl 
transferase enzyme activity specific for H3k4, while PRC2 complex containing EED, 
EZH2 and SUZ12 specifically mediates H3K27 methylation. 
  
target of chromosomal translocations observed in human acute leukemia (185).  MLL 
forms a HMT complex, in conjunction with other core component proteins, including the 
WD40-repeat protein WDR5, RbBP5 and Ash2L (186, 187) (Fig 1.4).  A deficiency of 
each of these subunits impairs MLL methyltransferase enzyme activity (186, 187). 
H3K27 trimethylation and H3K9 di- and trimethylation contribute to the maintenance of 
repressive chromatin structure and correlate with gene silencing (177, 188, 189).  Methyl 
H3K9 serves as a binding site for the chromodomain-containing protein heterochromatin 
protein HP1, which is essential for the establishment and maintenance of silent chromatin 
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(heterochromatin) (190, 191).  Methyl H3K27 offers a binding site for a chromodomain-
containing protein Polycomb, a core component of Polycomb repressive complex 1 
(PRC1), which together with PRC2 has a pivotal role in silencing the developmentally 
important Hox gene and X-chromosome inactivation (177).  PRC2 (also known as EED-
EZH2 complex) possesses several core components-Enhancer of Zeste 2 (EZH2), 
Suppressor of Zeste 12 (SUZ12), and embryonic ectoderm development (EED).  EZH2 
has a SET domain and possesses an intrinsic HMT enzyme activity, and methylation of 
H3K27 by EZH2 subsequently recruits PRC1, which exhibits a ubiquitin E3 ligase 
activity and influences gene transcription via the ubiquitylation of histone H2A (177). 
Interestingly, it has been observed that both H3K4me3 and H3K27me3 are present within 
regions enriched for genes encoding developmentally important TFs, which are proposed 
as “bivalent ” chromatin structure (192).  This observation suggests that bivalent domains, 
established by incorporation between permissive (H3K4me3) and repressive (H3K27me3) 
modifications, silence developmental genes in embryonic stem (ES) cells while keeping 
them poised for activation (192).  Thus, it has been argued that the balance between 
multiple chromatin modifications decides chromatin structure and gene transcription fate. 
            An expanding body of evidence has suggested that regulation by histone 
modification is dynamic, and that the presence of certain modifications may not 
necessarily correlate with the predicted regulatory status, i.e. turning genes “on” or “off”. 
It is the entire chromatin context containing multiple enzyme complexes with either 
cooperative or opposing effects that determine the overall outcome (160).  In support of 
this theory, there are some exceptions for the general concept of permissive and 
repressive histone modifications.  For example, methylation of H3K9, characteristic of 
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the silenced heterochromatin, was recently also shown to be associated with 
transcriptional elongation within active genes (193).  In contrast, permissive modification 
of H3K4me2 has been associated with silenced chromatin of centromeres in combination 
with H3K9 and H4K20 methylation.  Moreover, methyl H3K4 not only offers a binding 
site for permissive chromatin modifying-complexes, such as HAT-containing enzyme 
complex (194) and ATP-dependent nucleosome remodeling factor (NURF) (195), but 
also can be recognized and bound by repressive chromatin modifying factors, such as 
HDAC1-containing complex (196).  One explanation of these seemingly contradictory 
findings is that these modifying complexes with opposing effects may function at 
different stages of gene transcription, such as initiation or elongation of transcription, 
thereby regulating gene expression from both positive and negative sides (160).  In 
summary, individual modification interacts with neighboring positive-acting or negative-
acting modifications.  The overall outcome of these modifications results in the dynamic 
regulation of chromatin structure and subsequently determines the fate of gene 
transcription.   
Epigenetic regulation of gene expression in immune system 
            Considering the property of inheritance and stability, the epigenetic mechanisms 
may be involved in the long-term maintenance of gene expression pattern in a particular 
cell.  It has been convincingly documented that the maintenance of “memory” for genes 
expressed by Th1 and Th2 cells depends on chromatin modifications including histone 
acetylation, methylation and DNA methylation.  The Th2 locus containing Il5, Rad50, 
Il13 and Il4 gene has been well characterized to exhibit distinct combinations of 
individual chromatin modifications, which correlate with different patterns of gene 
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expression (182).  Three stages are recognized during the development of a Th2 cell 
phenotype, including the initiation of Th2 differentiation, reinforcement of Th2 
phenotype, and maintenance of Th2 fate.  Multiple key TFs and signaling pathways are 
known to be essential for the first two stages, such as IL-4/IL-4R/STAT6 pathway, 
nuclear factor of activated T cells (NFAT), GATA3, et al (197, 198).  Deficiency of these 
molecules inhibits normal Th2 development both in vitro and in vivo (182, 197, 198).  
However, GATA3, a Th2-specific TF, is not absolutely required for IL-4 production 
during the maintenance stage of Th2 cells, since conditional depletion of GATA3 in 
differentiated Th2 cells only results in a minor decrease in IL-4 production without 
affecting the total number of cells capable of producing IL-4 (199).  This observation 
strongly suggests that differentiated Th2 cells have acquired “cellular memory” of Th2 
cytokine production without the further requirement of polarizing signals, which are 
essential for the initial establishment of this memory.  Indeed, subsequent studies of 
chromatin modifications in Th2 locus during Th1/Th2 development have revealed that 
Th2 memory was conferred by permissive histone modifications, while repressive 
modifications were associated with silencing of Th2 locus in differentiated Th1 cells 
(182).  Compared with naïve T cells, Th2 cells exhibit a striking increase in histone 
lysine acetylation (H3K4/9Ac) and H3K4me2 through Th2 locus, which are general 
indicators of gene activation (see above General Concept).  In contrast, Th1 cells show 
enhanced H3K27me3 in the Th2 locus, an indicator of repressive chromatin structure and 
associated with gene silencing, in which EZH2 plays an essential role (182, 200). 
Moreover, experiments exploring epigenetic changes in Ifng locus during Th1/Th2 
differentiation have shown that Th1 cells acquire permissive histone-acetylation marks 
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that are dependent on both STAT4 and T-bet (201), whereas Th2 cells exhibit enhanced 
H3K27me2 dependent on STAT6 and GATA3 (202).  Recent investigations of the role of 
MLL on immune system are consistent with these findings and reveal that memory Th2 
cells with heterozygous disruption of Mll gene (Mll+/-) show a deficient Th2 cytokine (IL-
4, IL-5 and IL-13) production.  This was associated with decreased GATA3 expression, 
presumably through the effect of impaired Gata3 locus histone modifications (203).  
Together, these data show that the long-term maintenance of Th1/Th2, or “Th1/Th2 
memory” correlates with distinct histone modifications. 
              In addition to the Th1/Th2 paradigm, the newly discovered effector T cell 
lineage, Th17, has also been linked to epigenetic changes in Il17 locus (204).  Compared 
with either Th1 or Th2 cells, Th17 cells exhibit an enhanced histone acetylation and 
H3K4me3 at the Il17 promoter region, which is consistent with the general regulatory 
concept discussed above.  A recent study from the Medzhitov group has expanded our 
understanding of epigenetic regulation and maintenance of gene expression in immune 
system to macrophages (205).  Restimulation of macrophages with LPS resulted in an 
attenuated inflammatory response (LPS tolerance), but maintained an intact antimicrobial 
response, which are represented by two kinds of genes, tolerizeable and non-tolerizeable, 
respectively.  Tolerizeable genes lose the permissive histone modifications, H4Ac and 
H3K4me3, at their promoter regions during a secondary challenge with LPS, and 
treatment with chemicals enhancing these modifications rescues the impaired gene 
production.  In contrast, non-tolerizeable genes are still able to mount the permissive 
histone modifications, H4Ac and H3K4me3, in response to a secondary LPS challenge, 
which correlate with intact capacity to transcribe specific genes.  Thus, this short-term 
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cellular memory of tolerized macrophages is at least in part due to the regulation of the 
gene expression pattern by epigenetic changes at gene-specific loci (206).  This study 
highlights the fact that analogues to adaptive immune cells, the cells of innate immune 
system are also capable of mounting epigenetic-influenced cell memory in response to 
specific external stimuli.  Regarding the essential role of the innate immune response in 
pathological conditions, including infections, cancer and autoimmune diseases, the 
epigenetic mechanism-mediated innate immune cell memory has significant clinical 
relevance.  Epigenetic memory in innate immune cells may potentially explain long-term 
maintenance of some disease conditions, presumably through the effects of aberrant cell 
phenotype and the maintenance of inappropriately expressed genes, leading to 
immunoparalysis induced by severe sepsis, or macrophage polarization (M1/M2) in 
tumorgenesis (131).  Further investigations are required to characterize the molecular 
mechanism(s) responsible for epigenetic changes and the establishment of cell memory. 
            In summary, to explore the long-term alterations in DC function after severe 
sepsis, my graduate research work has addressed the following issues: 
1. Role of CCR6 in severe sepsis. 
2. Long-term effects of severe sepsis on DC functions, including cytokine 
production, Ag-presenting function, and Th1/Th2 polarizing capacity. 
3. Contribution of epigenetic changes to the regulation of cytokine genes in post-
septic DC in the context of long-term immunoparalysis after severe sepsis. 
4. Immunological consequences of severe sepsis on a subsequent immune response 




The chemokine receptor CCR6 is an important component of the innate immune 
response 
Summary  
            In our initial studies we found that naïve CCR6-deficient (CCR6-/-) C57BL/6 mice 
possessed significantly lower numbers of both F4/80+ macrophages and DCs, but higher 
numbers of B cells in the peritoneal cavity, as compared to naïve WT controls. 
Furthermore, peritoneal macrophages isolated from CCR6-/- mice expressed significantly 
lower levels of inflammatory cytokines and NO following LPS stimulation, as compared 
to WT macrophages.  In a severe experimental peritonitis model induced by cecal ligation 
and puncture (CLP), CCR6-/- mice were protected when compared with WT controls.  At 
24 hours following the induction of peritonitis, CCR6-/- mice exhibited significantly 
lower levels of inflammatory cytokines/chemokines in both the peritoneal cavity and 
blood.  Interestingly, DC recruitment into the peritoneal cavity was impaired in CCR6-/- 
mice during the evolution of CLP-induced peritonitis.  Peritoneal macrophages isolated 
from surviving CCR6-/- mice 3 days after CLP-induced peritonitis exhibited an enhanced 
LPS-response compared with similarly treated WT peritoneal macrophages.  These data 
illustrate that CCR6 deficiency alters the innate response by attenuating the hyperactive 




            Despite advances in intensive care unit interventions and the use of specific 
antibiotics, sepsis with concomitant multiple organ failure is the most common cause of 
death in many acute care units.  In this setting, approximately one-third of 750,000 
people annually affected by sepsis die (4, 5, 207, 208).  Sepsis is characterized by an 
initial overwhelming systemic inflammatory response syndrome (SIRS) (also known as a 
cytokine storm), which is followed by a compensatory anti-inflammatory response 
syndrome (CARS) (9).  Innate immune cells, including macrophage, PMNs and DCs are 
the main inflammatory cell types responsible for excessive cytokine production during 
the evolution of this response.  These cells both produce and respond to proinflammatory 
cytokines and chemokines, suggesting that they might be appropriate targets for the 
treatment of severe sepsis.  A number of novel therapeutics, specifically developed to 
prevent sepsis-induced mortality have failed, with the exception of recombinant activated 
protein C (28), supporting the concept that severe sepsis is dynamic and complex disease.   
            Chemokines are a family of structurally related chemotactic proteins, whose 
functions have been well studied on many fundamental aspects of immunology, including 
the development, homeostasis and host inflammatory response.  The effects of specific 
chemokines/chemokine receptors in the initiation and the progression of severe 
experimental sepsis have been previously reported, due to divergent and varied 
mechanisms (209-215).  However, the role of CCR6 in severe sepsis has not been 
previously investigated.  
            Interestingly, unlike most of the chemokine family members, CCR6 has only one 
chemokine ligand, CCL20, although β-defensin has been reported to bind CCR6 with a 
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lower affinity (216).  CCR6 has been shown to be expressed on immature DCs (135, 216, 
217), memory T cells  (218) and B cells (219), suggesting that CCR6 plays an important 
role in adaptive immunity.  This notion is further exemplified by CCR6/CCL20-
dependent immature DC migration, which is an essential mechanism for CD8+ T cell 
activation and host immunity against invasive pathogens in the skin and GI tract, 
respectively (87, 136).  CCR6/CCL20 has also been reported to be involved in 
lymphocyte-mediated chronic inflammation, such as asthma (217) and chronic 
obstructive pulmonary disease (COPD) (220).  Little is known about the role of CCR6 in 
innate immunity, except that CCL20 has been shown to direct the recruitment of NK cells 
(221). 
            The aim of the present study is to evaluate the contribution of CCR6 to the 
systemic inflammatory response and in vivo outcome in an experimental sepsis model 
induced by cecal ligation and puncture (CLP).  We demonstrate that deficiency of CCR6 
(CCR6-/-) alters peritoneal cellularity in naïve mice and renders mice resistance to CLP-
induced mortality.  In the latter situation, the absence of CCR6 was associated with 
dramatically lower peritoneal and systemic cytokine levels.  The number of DCs was 
significantly decreased in naïve CCR6-/- mice and the recruitment of DCs was impaired 
during severe sepsis, which supports the concept that CCR6 is involved in DC 
recruitment to inflammatory sites.  Furthermore, CCR6-/- peritoneal macrophages show 
an attenuated response to TLR agonist stimulation compared with similarly treated WT 
control.  The latter information may provide the mechanism for the lower levels of 
inflammatory cytokines and the survival advantage in CCR6-/- mice.  Thus, this study 
demonstrates that CCR6 deficiency modulates the initial local immune response and 
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alters subsequent inflammatory cascades normally associated with systemic immune 
reactivity.  
 
Materials and Methods 
Mice 
Specific pathogen-free female C57BL/6 WT mice were purchased from Taconic Farms, 
Inc. (Germantown, NY).  Female CCR6-deficient (CCR6-/-) mice were originally 
generated in Dr. Sergio A. Lira’s laboratory and were subsequently backcrossed eight 
generations onto a C57BL/6 background (137, 217).  Mice were housed in the animal 
care facility at the University of Michigan.  The University Committee on Use and Care 
of Animal (UCUCA) at the University of Michigan approved all experimental procedures. 
Experimental sepsis induced by CLP 
CLP surgery was performed on mice as previously described (222).  In brief, mice were 
anesthetized with an i.p. injection of 2.25 mg of ketamine HCL (Abbott Laboratories, 
Chicago, IL) and 150 µg of xylazine (Lloyd Laboratories, Shenandoah, IA).  Under 
sterile surgical conditions, a 1-cm midline incision was made to the ventral surface of the 
abdomen, and the cecum was exposed.  The cecum was partially ligated at its base with a 
3.0 silk suture and punctured nine times with 21-gauge needle.  The cecum was returned 
to the peritoneal cavity, and the abdominal incision was closed using surgical staples. 
Mice were rehydrated with 1 ml saline s.c. and placed on a heating pad until they 
recovered from anesthetic.  At 4, 24 and 72 h after surgery, CLP mice were anesthetized 
and bled.  Peritoneal lavage was performed with 2 ml of cold sterile saline.  Serum and 
cell-free peritoneal fluid were collected for chemokine/cytokine protein analyses.  RBCs 
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were lyzed in ammonium chloride buffer (150 mM NH4CL, 10 mM NaHCO3, 1mM 
EDTA- tetrasodium), and the total cell numbers were determined using a hemocytometer. 
Cytospins (Shandon Inc., Waltham, MA) were prepared and stained with Diff-Quik 
solutions (Dade Behring, Dudingen, Switzerland).  The leukocyte composition was 
analyzed, and the percentage of PMNs and mononuclear cells was multiplied by the total 
cell count to determine their absolute number. 
Survival studies following CLP 
The first set of survival studies was performed to determine the effect of the presence of 
CCR6 on survival in CLP-induced sepsis animal model.  WT and CCR6-/- mice were 
subjected to CLP surgery in the presence or absence of the treatment with antibiotic 
INVANZ (Ertapenem) i.p. injected at 75mg/kg (Merck & Co. Inc., Whitehouse station, 
NJ) 6 h after surgery and every 24 h until day 3 post-CLP.  Survival was monitored for 6 
days following surgery.  The second set of survival studies focused on the role of 
endogenous CCL20 following induction of acute septic peritonitis.  WT mice were i.p. 
injected with 20 µg/per mouse of anti-mouse CCL20 monoclonal antibody (R&D 
systems, Rochester, MN) 2 h before CLP and every day following surgery to block 
endogenous CCL20.  Rat IgG1 was used as a control. Survival was monitored for 6 days 
following surgery. 
Flow cytometry analysis 
Total peritoneal cells were harvested by peritoneal lavage with 10 ml cold sterile saline 
for 2 times from naïve WT or CCR6-/- mice or at indicated time points following CLP. 
After lysing RBCs with ammonium chloride buffer, total cell numbers were determined 
using a hemocytometer.  Fc binding was blocked via a 10 min incubation with purified 
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rat anti-mouse CD16/CD32 (FcγIII/II receptor).  Then the cells were stained with the 
following monoclonal antibodies to identify series of mouse cell types: PE-conjugated 
anti-CD11b in combination with FITC-conjugated anti-F4/80 (macrophage), FITC-anti-
CD19 (B cell), PE-anti-I-Ab in combination with FITC-anti-CD11c (DC), PE-anti-NK1.1 
(NK cell), PE-anti-CD4 in combination with FITC-anti-CD8 (CD4+ and CD8+ T cell). 
The appropriate IgG isotypes were used as controls.  All antibodies and IgG isotypes 
were purchased from BD PharMingen (San Diego, CA), except for anti-F4/80 (Serotec, 
Raleigh, NC).  The cells were fixed in 1% paraformaldehyde and kept in the dark at 4°C 
until analysis with a FACSCaliber (CELLQuestTM software; Becton and Dickinson, 
Mountain View, CA). 
Peritoneal macrophage collection and in vitro stimulation 
Total peritoneal cells were harvested by peritoneal lavage with 10 ml cold sterile saline 
performed twice for WT or CCR6-/- mice in naive status or at day 3 post-CLP.  Lavage 
was pooled for mice in the same group.  RBCs were lyzed in ammonium chloride buffer. 
The remaining cells were thoroughly washed with saline and counted in a hemocytometer. 
Cytospins were prepared and stained with Diff-Quik solutions, and the number of 
peritoneal macrophages was determined.  Cells were resuspended at a concentration of 
106 macrophages/ml in RPMI 1640 (BioWhittaker, Walkersville, MD) supplemented 
with 5% FCS, 2mM L-glutamine, 100 U/ml penicillin, and 100 µg streptomycin. 
Macrophages were plated in plastic 48-well cell culture plate (4X105/well) (Corning Inc., 
Acton, MA) and incubated 2 h at 37°C in 5% CO2.  Nonadherent cells were removed, and 
adherent cells were washed with complete RPMI 1640 medium, followed by the 
stimulation with 1 µg/ml LPS (Sigma-Aldrich, St. Louis, MO).  Four hours later, total 
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RNA was isolated from cultured peritoneal macrophages using Trizol reagent and 
quantitative Real-time PCR (TaqMan) was performed to measure cytokine/chemokine 
gene expression.  Twenty-four hours later, cell-free supernatant from each sample was 
collected and stored in -80°C until cytokine/chemokine protein assay by ELISA.  For the 
LPS rechallenge experiments, isolated peritoneal macrophages were pretreated with 10 
ng/ml LPS for 24 hours, washed twice and then exposed to a second challenge with 1 
µg/ml LPS.  Twenty-four hours later, the supernatants were collected to measure 
cytokine protein levels by ELISA. 
RNA isolation and real-time PCR (TaqMan) 
Total RNA was isolated from cultured peritoneal macrophages using Trizol (Invitrogen, 
Carlsbad, CA) according to the manufacturer’s directions.  A total of 2.0 µg of RNA was 
reverse transcribed to yield cDNA in a 25µl reaction mixture containing 1X first strand 
(Life Technologies, Gaitherburg, MD), 250 ng of oligo (dT)12-18 primer, 1.6 mM dNTPs 
(Invitrogen), 5 U of RNase inhibitor (Invitrogen), and 100 U of Moloney murine 
leukemia virus reverse transcriptase (Invitrogen).  Complementary DNA was then 
analyzed by quantitative, real-time PCR using a TaqMan 7500 sequence detection system 
(Applied Biosystems).  GAPDH was analyzed as an internal control.  The fold 
differences in mRNA expression between treatment groups were determined by the 
Sequence Detection Systems software (Applied Biosystems). 
ELISA                
Concentrations of IL-10, IL-12p70, TNF-α, CCL2, CCL3, CXCL10 were measured in 
cell-free peritoneal lavage fluid, serum, and cell culture supernatants using a standardized 
sandwich ELISA technique as previously described in detail (217, 223).  Briefly, C96 
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Maxisorp Nunc-Immuno plates (Fisher Scientific) were coated with 1-5 µg/ml capture 
Abs in coating buffer overnight at 4°C and washed with PBS containing 0.05% Tween 20. 
All Abs used for ELISA were purchased from R&D Systems.  Nonspecific binding sites 
were blocked with 2% BSA in PBS for 90 min at 37°C.  Plates were rinsed four times 
with wash buffer and cell-free supernatants were loaded and incubated for 1 h at 37°C.  
After four washings, a biotinylated detection polyclonal Ab was added for 45 min at 
37°C.  The plates were washed again and peroxidase-conjugated streptavidin (Bio-Rad) 
was added to the well for 30min at 37°C.  Plates were washed, and after the addition of 
chromogen substrate (Bio-Rad), OD readings were measured at 490 nm using an ELISA 
plate reader.  Recombinant murine cytokines were used to generate the standard curves 
from which the concentrations present in the samples were calculated. The limit of 
detection of the assays was 50 pg/ml. 
Nitrite production 
Nitrite (NO2–) levels were determined using the Griess method as previously described 
(224).  The measurement of this parameter is widely accepted as indicative of NO 
production.  Briefly, naive peritoneal macrophages were plated at 4 x 105/well of a 96-
well cell culture plate (Corning) and rested overnight.  Cells were treated with fresh 
complete RPMI 1640 medium alone, 20 U/ml IFN-γ (PeproTech), 100 ng/ml LPS, or 
both IFN-γ and LPS.  After 48 h at 37°C in 5% CO2, 50 µl of cell-free supernatants was 
transferred to a flat-bottom 96-well plate and treated with 100 µl of 0.5% sulfanilamide 
(Sigma) and 0.05% naphthylethylenediamine dihydrochloride (Sigma) in 2.5% 
phosphoric acid (H3PO4).  The absorbance was read at 550 nm in a microplate reader.  A 
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standard curve was generated using known concentrations of NaNO2 (Sigma).  Similar 
results were shown in three independent experiments. 
Statistics 
Statistical analysis was carried out with Prism 4 for Macintosh.  In survival studies a log-
rank test was used to test for significance.  For all other studies results are presented as 
the mean±SEM, and unpaired Student’s t test was applied to evaluate significance. 
Values of p<0.05 were considered statistically significant. 
 
Results 
Depletion of CCR6 alters inflammatory cell populations in naïve mice 
            Given that CCR6 has been reported to regulate DC localization in Peyer’s patches 
(137, 138), we tested whether the depletion of CCR6 alter the localization of resident cell 
populations in the peritoneal cavity of naïve mice.  Flow cytometric analysis was used to 
compare the numbers of several resident peritoneal cell types between WT C57BL/6 
(CCR6+/+) and C57BL/6 CCR6-/- mice.  Whereas there was no difference in the number 
of total peritoneal cells between two groups, we found CCR6-/- mice had significant 
fewer CD11b+F4/80+ macrophages (50.4±7.7×104 vs 72.4±8.4×10 4/per mouse, n=5) and 
CD11c+MHCII+ DCs (0.8±0.1×104 vs 1.5±0.2×10 4/per mouse, n=5) compared with WT 
controls (Table 2.1).  In contrast, there were significantly more CD19+ B cells in the 
peritoneal cavities of CCR6-/- mice compared with controls (1.5±0.25×106 vs 1.2±0.3×10 
6/mouse, n=5) (Table 2.1).  No difference was found in the number of peritoneal CD4+ 
and CD8+ T cells, as well as NK cells between the CCR6-/- and WT groups.  Therefore, 
CCR6 depletion alters the normal composition of peritoneal cells and results in a 
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Table 2.1 Peritoneal leukocyte subsets in naive mice a 
       Group                            CCR6+/+                CCR6-/- 
  Total cells 293.5±46             305.5±48.8 
  CD11b+ F4/80+ b 72.4±8.4             50.4±7.7 
  CD19+ b 115.5±27.6          151.6±25.4 
  CD4+ 15.3±0.4             18.7±0.4 
  CD8+ 4.8±0.3                 5.9±0.3 
  NK1.1+ 3.1±0.4              2.7±0.4 
  CD11c+ MHCII+ b 1.5±0.2              0.8±0.1 
a All values are (X104)/per mouse 
b Significant difference between the two groups 
 
decrease in the cell types of myeloid origin, but an increase in B cell number.  
Naïve CCR6-/- peritoneal macrophages display an attenuated LPS-response 
            Macrophages are major participants in innate immunity, because of their ability to 
phagocytose pathogens, generate cytotoxic oxygen and nitrogen intermediates, and 
express chemokines and cytokines that either attract or activate other immune cells. 
However, the overproduction of inflammatory factors during host defense leads to serious 
deleterious effects in normal tissues if left uncontrolled.  We next sought to determine 
whether the presence of CCR6 affected the production of peritoneal macrophage-derived 
inflammatory mediators.  Peritoneal macrophages from WT and CCR6-/- mice were 
harvested by peritoneal lavage and stimulated with 1µg/ml LPS.  After 4 h, CCR6-/- 
peritoneal macrophages contained significantly lower mRNA levels of IL-12p35, IL-
12p40, IL-10, TNF-α, CCL2, CCL3 and CXCL10 (Fig 2.1A).  Furthermore, after 24 h of 
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stimulation with LPS, CCR6-/- peritoneal macrophages produced significantly lower 
protein levels of IL-12p70, IL-10, TNF-α, CCL2, CCL3 and CXCL10 (Fig 2.1B), which 
is consistent with their mRNA levels after 4 h of LPS stimulation.  
 
Figure 2.1 Cytokine production by peritoneal macrophages from naive WT and 
CCR6-/- mice.  Peritoneal macrophages were collected by peritoneal lavage and 
stimulated with 1 µg/ml LPS.  Messenger RNA levels (A) and protein production (B) of 
inflammatory cytokines were measured by Taqman and ELISA, respectively.  (C) Nitrite 
production was measured following the activation of peritoneal macrophages with 20 
U/ml IFN-γ, 100 ng/ml LPS, or both IFN-γ and LPS.  (D) Messenger RNA levels of 
mannose receptor, FIZZ1 and arginase 1 were measured by Taqman.  (E) Protein level of 
FIZZ1 was measured by ELISA.  The results shown are representative of 5 experiments 
and are expressed as mean ± SEM.  * P≤0.05 compared with cytokine levels measured in 
WT peritoneal macrophages, n=5. 
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            Naïve CCR6-/- peritoneal macrophages were also assessed for the levels of nitrite, 
which reflect the expression of NO, one of the major macrophage-derived effector 
molecules that is cytotoxic (225) and can induce host tissue injury (226).  Peritoneal 
macrophages isolated from CCR6-/- mice generated significantly lower level of nitrite in 
response to either a 100 ng/ml LPS challenge (3.7 ± 1.0 vs 8.3 ± 1.1 µM, n=5), or 
challenged with LPS plus 20 U/ml IFN-γ (4.7 ± 0.98 vs 15.3 ± 2.2 µM, n=5), respectively, 
as compared to WT peritoneal macrophages (Fig 2.1C).  Collectively, our data indicated 
that the absence of CCR6 resulted in an attenuated LPS-response by naïve peritoneal 
macrophages. 
            Previously, our group has shown that CCR4-/- peritoneal macrophages exhibited a 
constitutive phenotype of alternative activation (227).  Since we observed that CCR6-/- 
peritoneal macrophages showed an attenuated LPS-response, we further tested if CCR6-/-
macrophages were also skewed to alternative activation status.  Alternative activated 
macrophages has been tightly linked to the upregulation of several molecules, including 
mannose receptor (MR), arginase 1 and the found in inflammatory zone 1 (FIZZ1) (227). 
There was no difference in mRNA levels of MR, arginase 1 and FIZZ1 between CCR6-/- 
and WT peritoneal macrophages in response to either medium alone or LPS (Fig 2.1D). 
Both WT and CCR6-/- peritoneal macrophages generated similar amount of FIZZ1 
protein in in vitro culture system (Fig 2.1E).  These data suggest that CCR6-/- peritoneal 
macrophages are not skewed to alternative activation. 
CCR6-/- mice are resistant to CLP-induced peritonitis 
            The difference in LPS-response between WT and CCR6-/- peritoneal macrophages 
prompted us to test the role of CCR6 in an experimental model of severe sepsis induced 
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by CLP.  In initial studies, 100% mortality was observed in WT mice without antibiotic 
treatment as early as 3 days post-CLP (Fig 2.2A).  However, CCR6-/- mice were 
significantly protected from CLP-induced lethality (p=0.011), and showed a 25% 
mortality rate at day 2 and 38% mortality rate at day 6; these latter mice were long-term 
survivors.  Clearly, the absence of CCR6 provided a survival benefit compared with 
CCR6 competent mice.  Antibiotic treatment for 3 days following CLP attenuated the 
severity of CLP and increased survival rates both in the WT and CCR6-/- groups (Fig 
2.2B).  However, CCR6-/- mice were more resistant to CLP-induced mortality compared 
to WT controls (p=0.001).  Specifically, none of CCR6-/- mice died at day 3 after CLP.  
At day 6 after CLP, 88% of the CCR6-/- mice were alive compared with 25% of the WT 
mice.  
 
Figure 2.2 Survival study during CLP-induced severe sepsis.  WT and CCR6-/- mice 
were subjected to CLP surgery, either in the absence (A) or presence (B) of antibiotics 
treatment.  Survival was monitored for 6 days following surgery. Each group: n=10. 
 
CCR6-/- mice express an attenuated cytokine profile after CLP-induced peritonitis  
            The polymicrobial peritonitis induced by CLP is associated with an amplified 




Figure 2.3 Cytokine profile in WT and CCR6-/- mice following CLP operation.  To 
compare the production of inflammatory cytokines in peritoneal cavities (A) and blood 
(B) between WT and CCR6-/- mice after CLP, ELISA was performed to measured protein 
levels of IL-12p70, IL-10, TNF-α, KC, CCL2, CCL3 and CxCl10 in peritoneal lavage 
fluid and serum.  * P≤0.05 compared with cytokine protein levels measured in WT mice 
24 h after CLP, n=5.  The results shown are representative of 3 individual experiments. 
 
and chemokines are augmented (228).  We compared the cytokine profiles in peritoneal 
lavage fluid and blood between WT and CCR6-/- mice before and after CLP-induced 
peritonitis.  Compared to WT mice, CCR6-/- mice produced a similar amount of 
inflammatory cytokines, including IL-12p70, IL-10, TNF-α, KC, CCL2, CCL3 and 
CXCL10 in peritoneal cavity and blood at 4 h after surgery.  However, CCR6-/- mice 
showed significantly lower levels of inflammatory cytokines both in the peritoneal cavity 
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(Fig 2.3A) and in blood (Fig 2.3B) at 24 h after CLP-induced peritonitis.  We also 
observed that CCR6-/- mice had significantly lower levels of inflammatory cytokines in 
both the lung and liver, as compared to WT controls (data not shown).  
Leukocyte recruitment into the peritoneal cavity post CLP-induced peritonitis 
            Based on the observation that CCR6-/- displayed a decreased cytokine production 
in mice, we designed a set of investigations to determine if the alterations were due to 
changes in leukocyte recruitment into the peritoneal cavity following CLP-induced 
peritonitis.  Two methods were used to assess leukocyte peritoneal infiltration in WT and 
CCR6-/- mice at various times after CLP (Fig 2.4).  Cytospins were prepared and the 
leukocyte composition, including PMNs and mononuclear cells, was determined by 
microscopic differential counting.  No difference in total numbers of leukocytes (Fig 
2.4A), mononuclear cells (Fig 2.4B) and PMNs (Fig 2.4C) in the peritoneal cavity was 
observed between the two groups of mice after CLP-induced peritonitis.  Our earlier 
observations demonstrated a difference in cellular composition in the peritoneal cavity 
between naïve WT and CCR6-/- mice and other investigations showed alterations in the 
recruitment of immature DCs during inflammatory responses (87, 136).  Thus, we 
investigated changes in DC population in CCR6-/- mice and found significantly fewer 
MHCII+CD11c+ DCs in the peritoneal cavity before and 4 and 24 hours after CLP-
induced peritonitis, as compared to WT mice (Fig 2.4D).  However, no difference was 
observed in the number of CD11b+F4/80+macrophage (data not shown). 
CCL20 showed no effect on peritoneal macrophages and CLP-induced mortality  
            CCL20, the only chemokine ligand for CCR6, is upregulated during inflammation 




Figure 2.4 Leukocyte recruitment into the peritoneal cavity in WT and CCR6-/- mice 
during CLP-induced sepsis.  WT and CCR6-/- mice (n=5/group/time point) were 
sacrificed at 4 h, days 1 and 3 after CLP surgery.  Naive mice were used as baseline 
values.  Peritoneal lavage was performed to collect total peritoneal cells.  (A) Total 
peritoneal cell numbers were determined using a hemocytometer.  (B, C) Cytospins were 
prepared.  The absolute numbers of mononuclear cells and PMNs were determined by 
multiplying the percentage of cells by the total cell count.  (D) Peritoneal cells were 
stained with PE-anti-I-Ab in combination with FITC-anti-CD11c, followed by flow 
cytometry analysis.  The results shown are representative of two experiments and are 
expressed as mean ± SEM.  * P≤0.05 compared with the number of MHCII+CD11c+ DCs 
in peritoneal cavity of WT mice in naïve status, or 4 and 24 h after CLP. 
  
in the peritoneal cavity was observed in WT mice with CLP-induced peritonitis with a 
peak at 24 h (Fig 2.5A).  CCR6-/- mice showed a significantly lower level of CCL20 in 
the peritoneal cavity 24 hours after CLP-induced peritonitis, as compared to WT mice, 
which was consistent with other inflammatory cytokines.  This might be due to an 
attenuated inflammatory response in CCR6-/- mice.  We next sought to determine whether 
the presence of CCL20 exacerbated the dysregulated immune response and promoted 
CLP-induced mortality in WT mice. When endogenous CCL20 was passively neutralized 
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with anti-CCL20 2 h prior to CLP-induced peritonitis and each following day, survival 
was not altered, as compared to mice treated with IgG control (Fig 2.5B).  These data 
suggested that the interaction between CCL20 and CCR6 was not involved in the survival 
of CCR6-/- mice after CLP-induced peritonitis.  We also tested whether CCL20 altered 
the LPS-response of WT peritoneal macrophages.  LPS induced inflammatory cytokine 
production by WT peritoneal macrophages, which was not altered by the presence of 
CCL20 in either low (1ng/ml) or high (100 ng/ml) concentrations (Fig 2.5C). 
 
Figure 2.5 Effects of CCL20 in CLP-induced mortality and LPS-response of WT 
peritoneal macrophages.  (A) WT and CCR6-/- mice (n=5/group/time point) were 
subjected to CLP operation.  Peritoneal lavage fluid was collected from naïve WT and 
CCR6-/- mice and at 4, 24, 72 hours post-CLP.  ELISA was performed to measure CCL20 
level.  * P≤0.05 compared with CCL20 level in peritoneal lavage fluid from WT mice at 
24 hours post-.  (B) WT mice were subjected to CLP surgery in the presence of 
antibiotics treatment.  Endogenous CCL20 was blocked by anti-CCL20.  Rat IgG1 was 
used as a control. Survival was monitored for 6 days following surgery.  Each group: 
n=10.  (C) Peritoneal macrophages were collected from WT mice and stimulated with 
LPS in the absence or presence with either 1ng/ml or 100 ng/ml recombinant murine 
CCL20 protein.  Twenty-four hours later, cell culture supernatants were collected and 




Figure 2.6 Cytokine production by peritoneal macrophages from WT and CCR6-/- 
mice day 3 post-CLP.  WT and CCR6-/- mice (n=5) were sacrificed at day 3 after CLP 
surgery.  Peritoneal macrophages were collected by peritoneal lavage and exposed to 1 
µg/ml LPS.  (A) Four hours after LPS stimulation, mRNA levels of inflammatory 
cytokines in peritoneal macrophages were measured by Taqman.  *, τ P≤0.05 compared 
with mRNA levels of inflammatory cytokines in WT peritoneal macrophages.  (B) 
Twenty-four hours after LPS stimulation, protein levels of inflammatory cytokines in 
culture supernatants were measured by ELISA.  α, β P≤0.05 compared with protein 
levels of inflammatory cytokines produced by WT peritoneal macrophages. 
 
CCR6-/- macrophages show enhanced LPS-responsiveness after CLP-induced 
peritonitis  
            It has been well established that macrophages develop a unresponsiveness to LPS 
challenge after LPS pretreatment, a process referred to as endotoxin tolerance (232).  The 
mechanism for this tolerance response is not fully clear.  Since we observed that CCR6-/- 
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mice had an attenuated inflammatory immune response and higher survival rate during 
CLP-induced severe sepsis, we investigated whether the septic response induced LPS 
tolerance in CCR6-/- peritoneal macrophages.  We initially focused on cytokine 
production in response to LPS stimulation.  Three days after CLP, the levels of 
inflammatory cytokines generally decreased to the base line, indicating the end of the 
acute phase of severe sepsis.  In contrast to naïve macrophages, CCR6-/- peritoneal 
macrophages, at day 3 after CLP-induced peritonitis, had significantly higher LPS-
induced mRNA levels of IL-12p35, IL-12p40, IL-10, TNF-α, CCL3 and CXCL10, but 
lower CCL2 mRNA level compared with WT peritoneal macrophages isolated at the 
same time after CLP (Fig 2.6A).  Consistently, after 24 h of stimulation with LPS, CCR6-
/- peritoneal macrophages produced significantly higher protein levels of IL-12p70, IL-10, 
TNF-α, CCL3 and CXCL10, but less CCL2 (Fig 2.6B).  These data suggest that CCR6-/- 
peritoneal macrophages do not exhibit classical LPS-induced tolerance. 
          To test if the greater LPS-responsiveness of CCR6-/- macrophages day 3 after CLP-
induced peritonitis is an intrinsic property of CCR6-/- macrophages, or it is because of an 
attenuated cytokine storm affecting CCR6-/- peritoneal macrophages during CLP-induced 
peritonitis (Fig 2.3A), we next performed a classical LPS rechallenge experiment using 
ex vivo peritoneal macrophage isolated from naïve WT and CCR6-/- mice.  Naïve CCR6-/- 
peritoneal macrophages produced significantly lower protein levels of IL-12p70, IL-10, 
TNF-α, CCL2, CCL3 and CXCL10 in response to one-time LPS challenge compared to 
similarly treated WT control, which we have previously observed (Fig 2.1).  Both WT 
and CCR6-/- peritoneal macrophages, which have been pretreated with 10 ng/ml LPS, 
showed unresponsiveness to a second challenge with 1µg/ml LPS, indicating that CCR6-/- 
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peritoneal macrophages possessed a similar unresponsiveness to LPS challenge after LPS 
pretreatment as WT controls (Fig 2.7). 
 
Figure 2.7 LPS rechallenge of peritoneal macrophages from naive WT and CCR6-/- 
mice.  Peritoneal macrophages were collected by peritoneal lavage and pretreated with 
10ng/ml LPS for 24 hours.  After 2 times wash, these cells were stimulated with 1 µg/ml 
LPS for 24 hours.  Supernatants were collected to measure cytokine protein levels by 
ELISA.  * P≤0.05 compared with cytokine levels measured in WT peritoneal 
macrophages, n=5. 
 
            Since severe sepsis induces a long-term impairment in IL-12 production by DCs 
(chapter 3 and 4) and CCR6 deficiency alters cytokine production of peritoneal 
macrophages, we wondered if CCR6 has a role in severe sepsis-induced IL-12 
downregulation in DCs.  However, we observed a similar decrease in IL-12 production 
by splenic DCs following severe sepsis between WT and CCR6-/- mice (data now shown), 
which indicated that CCR6 is not involved in IL-12 downregulation in post-septic DCs.  
Further investigations have been carried out to study the molecular mechanisms of severe 




            In the present study, the role of CCR6 during experimental severe sepsis was 
investigated.  We found that mice lacking CCR6 exhibited a constitutive decrease in 
resident peritoneal macrophage populations, as well as DC numbers, as compared to WT 
mice.  Although cytokine production by pulmonary DCs and bone marrow–derived DCs 
in response to TLR agonist stimulation was comparable between WT and CCR6-/- mice 
(data not shown), we observed that naïve CCR6-/- peritoneal macrophage exibited a 
decreased production of inflammatory cytokines and NO in response to LPS stimulation 
compared with similarly treated WT controls.  CCR6-/- mice were significantly protected 
from CLP-induced lethality and showed an attenuated localized and systemic 
inflammatory cytokine production compared with WT mice.  Surprisingly, CCL20, the 
only chemokine ligand of CCR6, did not appear to play a role in the pathology of 
experimental sepsis, since localized neutralization of endogenous CCL20 had no effect 
on survival in septic WT mice, and CCL20 failed to influence the LPS-responsiveness of 
WT peritoneal macrophages.  
             Chemokines and chemokine receptors were originally described to be essential 
mediators directing homeostatic cell trafficking and cellular recruitment during 
inflammatory responses.  However, the biological activities of chemokines are more than 
chemotactic factors alone.  They are now known to play important roles in a variety of 
activities including maintenance of homeostasis, angiogenesis/angiostasis, wound healing, 
tumor growth and metastasis, cellular differentiation and activation, lymphocyte 
development and trafficking, lymphoid organ development, and influencing the type 
1/type 2 balance of immune responses (133, 134).  Monocyte/macrophage trafficking has 
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been shown to depend on the interactions between chemokines and chemokine receptors. 
For example, CCR2 mediated homeostatic monocyte emigration from bone marrow into 
circulation, and inflammation-induced monocyte recruitment from bone marrow to 
peripheral infected tissue also requires CCR2 signaling (233).  Although it has been 
reported that CCR2 was not involved in tissue entry of monocyte from the circulation 
(233), new data has shown that CCR2 is necessary for efficient monocyte recruitment 
from the blood into inflamed tissue (234).  CCR2-/- mice also show an impaired 
recruitment of macrophage into the peritoneal cavity in response to thioglycollate 
stimulation (235).  Thus, CCR2-/- mice exhibit deficient monocyte recruitment into 
inflected sites in response to a broad range of stimuli (236, 237).  
            While we were not surprised to observe a decrease in peritoneal DC population in 
naïve status and impaired DC recruitment in inflammatory responses in CCR6-/- mice, 
which was consistent with other studies (137, 138, 217, 220), it was not predicted that the 
population of peritoneal macrophages also was decreased.  In contrast to numerous 
reports showing monocyte/macropahge chemotactic property of chemokines and 
chemokine receptors, little is know about the influence of chemokine signaling on 
monocyte/macrophage lineage development and normal function.  The chemokine 
receptor CXCR4 has been reported to be expressed on hematopoietic stem cells (HSCs) 
and the interaction of CXCR4 with its cognate ligand, CXCL12, was essential for the 
colonization of bone marrow by HSCs during development (238).  CXCR4 was also 
involved in HSCs homing to bone marrow (239), as well as their survival and 
proliferation (240).  Thus, it is highly possible that chemokine signaling has a role in 
directing normal hematopoiesis, including the development of monocyte/ macrophage 
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lineage.  Our data showed that CCR6 controlled the localization of macrophages and DCs 
in the peritoneal cavity and altered the phenotype of naïve peritoneal macrophages, 
suggesting that CCR6 signaling may be involved in the development of 
monocyte/macrophage lineage.  However, the molecular mechanism whereby CCR6 
influences the development and function of peritoneal macrophages is not clear.  The 
possibilities are that CCR6 functions either during the development of monocyte/ 
macrophage lineage from progenitor cells in bone marrow, or influences migration of 
monocyte/ macrophage to peripheral tissues.  Thus, the role of CCR6 in the development 
of monocyte/macrophage lineage is worthy of further investigation. 
            A number of in vitro and in vivo studies have underscored the importance of 
chemokines/chemokine receptors in the initiation of the immune response to sepsis, as 
well as a direct correlation with tissue pathology, organ dysfunction and failure, and 
lethality.  Immunoneutralization of CXCR2 with specific antibody decreased PMN 
recruitment and CLP-induced lethality (212, 241).  CCR1-/- mice had accelerated 
cytokine production and were protected against the deleterious effects of sepsis, due in 
part to the fact that CCR1-/- peritoneal macrophages displayed both an early and enhanced 
cytokine/chemokine expression profile and anti-bacterial response.  CCR4 gene knockout 
has been shown to protect mice from systemic challenge with either LPS (214) or other 
TLR agonists, as well as protect mice against bacterial peritonitis (211).  CCR4-/- 
peritoneal macrophages were demonstrated to possess a constitutive phenotype of an 
alternatively activated macrophage and exhibit features associated with alternative 
activation, including enhanced production of type-2 cytokines, CCL2, CCL17 and the 
found in inflammatory zone 1 (FIZZ1) protein (211).  CCR8-/- mice were also resistant to 
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CLP-induced lethality, which mechanistically may be related to the phenotype of CCR8-/- 
peritoneal macrophages.  These inflammatory cells were highly activated, exhibited 
enhanced bactericidal activities, and generated high levels of superoxide, lysosomal 
enzymes and NO in response to LPS stimulation (210, 213).  Collectively, our data in the 
present study and the above reports suggests that chemokines/chemokine receptors have a 
role in the development and maintenance of normal function of peritoneal macrophage, 
since chemokine receptor deficiencies alter the functions of peritoneal macrophages, 
including cytokine production in response to TLR agonists.  
            Although CCL20 is the main ligand for CCR6, β-defensin has also been shown to 
bind CCR6 with a lower affinity (216).  Defensins, a family of arginine-rich cationic 
peptide, have direct antimicrobial effect and are considered to be an important effector 
molecule in innate immune response (242, 243).  Furthermore, defensins were also 
shown to chemoattract immune cells, including monocyte/ macrophages (244, 245), mast 
cells (246) and DCs (216).  This suggests that defensins contribute either directly or 
indirectly to the mobilization of host immune defense in response to pathological 
infections.  In the present study, we observed an attenuated inflammatory cytokine 
production and survival advantage in CCR6-/- mice during severe sepsis, which was not 
related to CCL20 function.  Thus, this finding raised the question whether β-defensin was 
involved in exacerbating dysregulated immune response and cytokine production in WT 
mice.  Interestingly, it has been shown that human α-defensin promoted the expression 
and production of CXCL5 and CXCL8 by bronchial epithelial cells (247) and increased 
the production of TNF-α and IL-1 by monocytes (248).  Thus, it is possible that, during 
CLP-induced bacterial peritonitis, β-defensin promoted the inflammatory cytokine 
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production by innate immune cells, including peritoneal macrophages and DCs in a 
CCR6-dependent mechanism.  
            In summary, we have shown that genetic depletion of CCR6 decreased 
mononuclear cells of myeloid origin including macrophage and DCs in peritoneal cavity. 
Peritoneal macrophages from CCR6-/- generated significantly lower amounts of 
inflammatory cytokines and NO compared with similarly treated WT controls. 
Furthermore, CCR6 depletion increased survival rate during CLP-induced severe sepsis, 
which was associated with an attenuated cytokine storm, an indicator of severity of sepsis. 
Moreover, peritoneal macrophages isolated from day 3 post-CLP CCR6-/- mice showed 
an enhanced LPS-response compared with WT control, indicating that these cells did not 
develop tolerance to bacteria-derived factors such as LPS, which is one of the key 
features associated with immunosuppression in patients who survive severe sepsis.  Thus, 
these data suggested that CCR6 is a key mediator in modulating the innate inflammatory 





Severe sepsis exacerbates cell-mediated immunity in the lung due to an altered 
dendritic cell cytokine profile 
Summary  
            Severe sepsis leads to long-term alterations in the immune response of surviving 
individuals.  We have modeled this alteration in host immunity by studying the survivors 
of severe experimental sepsis (murine cecal ligation and puncture-CLP), who were 
subsequently challenged with lung granuloma-inducing Schistosoma mansoni eggs.  This 
granulomatous response is a well-studied cell-mediated immune reaction, which is 
characterized by elevated levels of type-2 cytokines.  Pulmonary granulomas induced by 
S. mansoni eggs in CLP survivors were significantly larger and contained more 
eosinophils than granulomas in sham-operated mice.  Significantly lower IL-12p40 
mRNA and IL-12p70 protein levels were observed in the lungs of post-septic mice with 
developing granulomas, compared to controls.  Post-septic mice had significantly fewer 
dendritic cells (DCs) in the lungs during the granulomatous response.  Isolated lung DCs 
from post-septic mice at days 8 and 16 after S. mansoni egg challenge exhibited defective 
IL-12 synthesis, but enhanced IL-10 synthesis, following TLR agonist challenge. 
Pulmonary transfection with an IL-12 expressing adenovirus in post-septic mice reversed 
the skewing of the pulmonary cytokine profile and normalized the lung granulomatous 
response.  Our data indicates that severe sepsis shifts the pulmonary cytokine 
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environment, presumably via effects on pulmonary DCs, which in turn alters the lung 
cell-mediated immune response. 
 
Introduction 
            Sepsis is the most common cause of death in intensive care units, afflicting 
750,000 people and killing 210,000 people annually (4, 5, 208).  The initiation and 
maintenance of sepsis and acute lung injury are triggered by an initially exaggerated 
innate immune response leading to a cytokine storm, which has been extensively studied 
(9).  In contrast, the long-term consequence of severe sepsis on the host immune response 
has been poorly characterized.  During severe sepsis, dysregulation of the systemic 
immune response may result in either rapid death due to multiple organ failure (MOF) or 
susceptibility to secondary infections with bacteria, viruses or fungi due to long-term 
immunosuppression (38, 249).  The dramatic loss of DCs in septic patients and in animals 
with severe sepsis has been reported, which may significantly impair B and T cell 
function and contribute to the long-term defective adaptive immunity after the acute 
phase of sepsis (54, 57).  The respiratory system is most susceptible to secondary 
infections after severe sepsis and pulmonary complications often lead to mortality in this 
group of patients (47).  
            Previously, our lab has shown that mice that have recovered from cecal ligation 
and puncture (CLP) were susceptible to a pulmonary challenge of Aspergillus fumigatus 
whereas sham-operated mice were not (38, 39).  This previous study suggested that post-
septic mice had impaired innate pulmonary immunity, since A. fumigatus normally poses 
few problems to an intact pulmonary immune system (250).  To further investigate the 
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influence of severe sepsis on the pulmonary adaptive immune response, we used 
granuloma-inducing Schistosoma mansoni eggs as a pulmonary challenge in survivors of 
severe sepsis induced by CLP surgery.  
            Granulomatous immune responses induced by S. mansoni eggs are unique 
inflammatory sites and offer a rewarding model to study the evolving immune response 
(251).  The granulomatous response in the lung is not lethal to the host and thereby 
allows for the long-term study of the immune response.  During the pathological 
development of S. mansoni egg-induced granulomas, the host initiates a Th0 immune 
response, which subsequently switches to a type-2 immune response driven by 
alternatively activated macrophages, T-lymphocytes and eosinophils (143).  In addition, 
it has been shown that CD11c+ DCs are a notable component of S. mansoni granulomas 
and are involved in directing the pulmonary cytokine response (139, 141).  
            The purpose of this study was to investigate the long-term influence of severe 
sepsis on the adaptive immune response reproducibly elicited by S. mansoni eggs.  We 
demonstrate that mice, which survived CLP-induced severe sepsis, developed 
significantly larger granulomas.  The greater granulomatous response was associated with 
a selectively impaired type-1 and enhanced type-2 cytokine profile in the lung.  Study of 
lung DCs revealed a decrease in their recruitment.  In addition, pulmonary DCs showed 
the defective production of IL-12 and the enhanced production of IL-10.  Following the 
introduction of an IL-12-producing adenovirus vector, the skewed cytokine profile in the 
post-septic lung was reversed and the granulomatous response was normalized, but DC 
recruitment was not influenced.  Thus, this study highlights the adverse consequences of 
severe sepsis on the adaptive immune response in the lung.  IL-12 gene transfer in the 
 
 58 
post-septic lung appeared to rebalance the adaptive immune response and diminish the 
remodeling pathology associated with pulmonary granulomatous responses.  
 
Materials and Methods 
Mice 
Female C57BL/6 mice (6-8 wks; Taconic Company, Germantown, NY) were housed 
under specific pathogen-free conditions at The Unit for Laboratory Animal Medicine 
(ULAM) of the University of Michigan.  The animal ethical committee approved the 
experiments. 
Survivors of CLP subsequently challenged by S. mansoni eggs 
Sham and CLP surgery was performed as described in Chapter 2.  At day 3 post-surgery, 
both surviving CLP mice and sham-operated mice were intravenously injected with 5000 
viable S. mansoni eggs via the tail vein.  Live S. mansoni eggs were purified from the 
livers of S. mansoni cercariae-infected Swiss-Webster mice, which were kindly provided 
by Dr. Fred Lewis (Biomedical Research Laboratory, Rockville, MD). 
Morphometric Analysis of pulmonary granuloma and eosinophil count   
The left lung lobe from both sham and CLP groups at days 1, 2, 4, 6, 8, 16, and 30 after 
the intravenous S. mansoni egg challenge was fully inflated with 10% formalin, dissected, 
and placed in fresh formalin for an additional 24 hours.  Routine histological techniques 
were used to paraffin-embed lung tissue, and 5-µm sections were stained with 
hematoxylin and eosin (HE).  The structural alternations and eosinophil infiltration were 
examined around individual (ie. containing a single egg) pulmonary granulomas using 
light microscopy at a magnification of 200X and 1000X, respectively.  Morphometric 
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analysis of egg granuloma size was performed using the Scion Image 1.63 software 
program (Scion Corporation, Frederick, MD).  The number of eosinophils recruited to the 
granuloma were counted and normalized to the granuloma size.  A minimum of 15 
granulomas per lung section was analyzed for granuloma size and 25 granulomas per 
mouse were analyzed for the eosinophil infiltrate.  The same protocol was applied for the 
mice transfected with IL-12 expressing adenovirus. 
Cytokine and cytokines ELISA Analysis 
IL-4, IL-5, IL-10, IL-12p70 and IL-13 were measured in 50-µl samples from cell-free 
supernatants either from lower right lobes homogenates or from tissue culture plates using 
a standardized sandwich ELISA technique as described in Chapter 2. 
Quantitative Real-time PCR (Taqman) 
Analysis of transcripts with Taqman was performed as described in Chapter 2.  
Flow cytometry analysis 
Whole lungs were dispersed in 0.2 % collagenase (Sigma-Aldrich) in RPMI 1640 
(Mediateck, Inc.) + 5% fetal bovine serum (Atlas, Fort Collins, CO) at 37°C for 45 min. 
After lysing red blood cells with ammonium chloride buffer (4.01 g NH4Cl, 0.42 g 
NaHCO3, and 0.185 g tetrasodium EDTA in 500 ml dH2O), Fc binding was blocked via 
a 10-min incubation with purified rat anti-mouse CD16/CD32 (FcγIII/II receptor).  Then 
the cells were stained with either PE-labeled anti-CD11c (HL3) and FITC-anti-CD11b 
(M1/70) or PE-anti-CD11c and FITC-anti-CD45R/B220 (RA3-6B2) in Dulbeco’s PBS + 
0.2% BSA + 0.1% NaN3 for 30 min at 4°C in the dark.  The appropriate IgG isotypes 
were used as controls.  All antibodies and IgG isotypes were purchased from BD 
PharMingen (San Diego, CA).  The cells were fixed in 1% paraformaldehyde and kept in 
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the dark at 4°C until analysis with a FACSCaliber (CELLQuestTM software; Becton and 
Dickinson, Mountain View, CA). 
Pulmonary dendritic cell isolation and in vitro stimulation  
Dendritic cells were isolated from the pooled lungs from sham and CLP groups (n=5 
mice/group) at days 8 and 16 after the S. mansoni egg challenge, as described in the flow 
cytometry analysis section.  Then, cell suspensions were enriched with anti-CD11c 
magnetic beads and positive selection MS+ columns according to the manufacturer’s 
instructions (Miltenyi Biotec, Auburn, CA).  Briefly, the cells, re-suspended in 10-ml 
RPMI 1640, were incubated in 200mm cell culture dish (Corning Inc., Acton, MA) for 1 
hour at 37°C to remove the adherent macrophages.  Non-adherent cells were collected 
and resuspended in 400µl of buffer (1XPBS/0.5% BSA) containing 100µl of CD11c 
microbeads.  After a 15-min incubation at 4°C, free beads were washed away and the 
cells conjugated with beads were passed through MS+ columns for positive selection.  
The viability of the purified DCs was estimated by trypan blue staining.  The purity of 
these DCs was determined by either cell morphology using cytospin (Shandon Inc.) 
followed by hematoxylin-eosin (HE) staining or stained by PE-labeled CD11c and FITC-
labeled-MHCII followed by flow cytometry analysis.  Then the purified DCs were 
counted on a hemocytometer and subsequently diluted at 5X106/ml.  The aliquots of 
100µl containing these cells were added to 96-well plates.  A group of stimuli were added 
to the plated DCs including 100µg/ml S. mansoni egg antigen (SEA), 1µg/ml 
lipopolysaccharide (LPS), or 2.5µg/ml Pam3cys.  After 6 hrs of stimulation, total RNA 
was isolated using Trizol reagent and quantitative Real-time PCR (Taqman) was 
performed to measure IL-10 and IL-12 gene expression.  After 48 hrs of stimulation, cell 
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free supernatant from each sample was collected and stored in -80°C until the 
measurement of IL-12 and IL-10 protein levels by ELISA. 
IL-12 expressing adenovirus (AdmIL-12) intrapulmonary infection 
A recombinant human adenovirus expressing a functional heterodimeric mouse IL-12 
protein was generated as previously described (252).  The AdmIL-12 construct contains 
the p35 and p40 cDNA fragment inserted into the E1 and E3 regions of human type-5 
adenoviral genome.  Expression of both p35 and p40 cDNAs is driven by the human 
CMV immediate early promoter and terminated by the SV40 polyadenylation signal. 
Transfection with this replication-defective construct results in the expression of active 
IL-12 both in vitro and in vivo (252).  As a control, a previously described replication-
deficient, E1-deleted Ad70 construct was used (253).  At day 3 after CLP or sham 
surgery, mice were anesthetized with a combination of ketamine and xylazine, as 
described for the CLP procedure (see above).  The tracheas of mice were exposed by 
making 0.5-cm midline incision on the ventral surface of the neck.  Mice were 
intratracheally injected with 30µl saline containing 3X108 plaque-forming units of either 
AdmIL-12 or Ad70 and then immediately injected intravenously with 5000 S. mansoni 
eggs.  The adenoviral vector results in very efficient infectivity of the airway epithelium 
and produces high levels of IL-12 mRNA and protein in lung (254).  At 6, 8 and 16 days, 
the mice were sacrificed and the whole lungs were collected for histology, gene 
expression analysis (Taqman) and protein measurement (ELISA) (see above). 
Statistical analysis 
All results are expressed as mean ± standard error of the mean (SEM).  The means 
between sham and CLP groups at different time points were compared by two-way 
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ANOVA.  Individual differences were further analyzed using the Bonferroni post-tests. 
For the in vitro studies with lung DCs, the Mann-Whitney U test was used to compare the 
means between sham and CLP group. P<0.05 was considered statistically significant. 
 
Results 
Severe sepsis augmented the pulmonary granulomatous response  
            In order to investigate the long-term consequence of severe sepsis on the adaptive 
immune response in the lung, mice that survived three days following severe 
experimental sepsis induced by CLP were subsequently challenged intravenously with S. 
mansoni eggs.  Sham-operated mice were used as controls.  The formation and 
development of pulmonary granulomas induced by S. mansoni eggs have been previously 
well characterized in non-surgically manipulated mice (255, 256), thereby providing a 
paradigm for the study of this response in post-septic mice.  Histological examination of 
lung tissue revealed that S. mansoni egg-induced granulomas were similar in size in both 
sham and post-septic mice up to day 8 after egg injection (Fig 3.1A).  However, at day 16, 
post-septic mice exhibited significantly (p<0.001) larger granulomas (28498.3±1152.6 
µm2, n=5) compared with the sham mice (18882.2±814.1 µm2, n=5).  This difference was 
also present at day 30 after egg challenge (28232.7±1607.7 µm2, n=4 Vs. 14310.6±644.7 
µm2, n=5; p<0.001) (Fig 3.1B).  Quantification of eosinophil content in lung granulomas 
revealed that eosinophil number in post-septic mice at day 8 (0.525±0.026/100 µm2) and 
day 16 (0.999±0.052/100 µm2) were significantly greater than those in the sham mice at 
day 8 (0.370±0.025/100 µm2; p<0.01) and day 16 (0.612±0.040/100 µm2; p<0.001), 
respectively (Fig 3.1C). 
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Figure 3.1 The histology of pulmonary granulomas induced by S. mansoni eggs.  (A) 
Sham and CLP groups were challenged with 5000 live S. Mansoni eggs at day-3 post-
surgery.  The left lung lobe from both groups was collected at different time points for 
histological analysis.  H&E-stained lung sections from sham or CLP mice are shown.  (B) 
Quantification of granuloma size at a series of indicated time point after egg challenge.  * 
P≤0.05 compared with granuloma size measured in sham mice.  (C) Quantification of 
eosinophil number in pulmonary granulomas.  Each group: n=5∼6/time point.  The results 
shown are representative of three experiments and are expressed as mean ± SEM.  τ 
P≤0.05 compared with eosinophil number in the pulmonary granulomas from sham mice. 
 
Severe sepsis altered the cytokine profile in lung tissue 
            The changes in pulmonary granuloma size and cellular content in post-septic mice 
suggested that an altered immune status was present at this tissue site, therefore we 
hypothesized that this was associated with an altered cytokine profile.  The expression of 





















































Figure 3.2 Cytokine transcript expression in the lungs from sham and CLP mice. 
After egg challenge at day-3 post-surgery, mice from the sham or CLP groups were 
anesthetized and the upper right lobe was collected to investigate the gene expression 
level of IL-4, IL-5, IL-10, IL-12p40 and IL-13 in the whole lungs at days 1, 2, 4, 6, 8, 16 
and 30 post-egg challenge.  Total RNA was isolated and reverse transcribed to cDNA. 
Quantitative real-time PCR (Taqman) was performed to measure the transcript level of 
each cytokine.  The mRNA level of each sample was normalized by mRNA level in naïve 
mice and the data is shown as the fold of increase [2(-ΔΔCT)].  * P≤0.05 compared with IL-
12p40 mRNA level measured in the lungs of sham mice, n=4∼6. 
 
quantitative real-time PCR (Taqman) and at the protein level by ELISA.  IL-12p70 is a 
heterodimeric cytokine, which consists of covalently bound p40 and p35 subunits and has 
a central role in type-1 immune response (118).  In the present study, post-septic mice 
had significantly lower whole lung transcript level of IL-12p40 (Fig 3.2) and protein level 
of IL-12p70 (Fig 3.3) compared with sham mice at several time points up to day 8 after S. 
mansoni egg challenge.  For the type-2 related cytokines, no differences were observed at 
the transcript level for IL-4, IL-5, IL-10 and IL-13 between two groups (Fig 3.2). 
However, post-septic mice exhibited significantly higher whole lung IL-4 and IL-13 
protein levels at day 1 and IL-10 protein level at day 2 after egg challenge compared with 
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Figure 3.3 Cytokine protein levels in the whole lungs from mice of sham and CLP 
group.  To investigate the production of IL-4, IL-5, IL-10, IL-12p40 and IL-13 in the 
whole lungs of sham and CLP mice, the lower right lobes from sham or CLP mice were 
analyzed by ELISA and normalized to the total protein level. * P≤0.05 compared with IL-
12p70 protein level in the lungs of sham mice.  ϕ P≤0.05 compared with IL-4 level in the 
lungs of sham mice at day 1; τ P≤0.05 compared with IL-10 level in the lungs of sham 
mice at day 2; γ P≤0.05 compared with IL-13 level in the lungs of sham mice at day 1. 
 
S. mansoni eggs-induced DC recruitment to lung was impaired in post-septic mice 
            Given its accessory role during immune responses, DCs are recognized as one of 
the key initiators of adaptive immunity and have a pivotal role in directing the type-
1/type-2 cytokine response (72, 257-259).  Since the cytokine profile in the lung revealed 
an altered adaptive immune response in post-septic mice, we used flow cytometry to 
study the influence of severe sepsis on the presence of DC subpopulations in the lungs.  
In sham mice, peak percentages of two subpopulations of DCs, namely CD11c+CD11b+ 
DCs and CD11c+B220+ DCs, were observed in the lung at day 2 after egg challenge (Fig 
3.4).  However, lungs from post-septic mice contained significantly lower proportions of 
these two subpopulations of DCs at day 2 and day 8 after egg challenge when compared 
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to similar samples from sham mice.  At day 16 after egg challenge, DC percentages were 
similar in both groups of mice.  
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Figure 3.4 Severe sepsis impairs DC recruitment to pulmonary granulomas induced 
by S. mansoni eggs.  Mice from sham or CLP group (n=5∼7/group/time point) were 
sacrificed at days 2, 8 and 16.  Mice killed at day 0 did not receive eggs and were used as 
baseline values.  Lungs were digested by collagenase IV and the dispersed cells were 
stained as follows: CD11c+CD11b+ and CD11c+B220+.  These cell surface markers were 
assessed by flow cytometry analysis.  The results shown are representative of two 
experiments and are expressed as mean ± SEM.  * τ , P≤0.05 compared with 
CD11c+CD11b+ DCs and CD11c+B220+ DCs in the lungs of sham mice at days 2 and 8, 
respectively. 
 
Alteration in the cytokine production in pulmonary DCs induced by severe sepsis 
            The cytokine profile in the whole lung samples revealed a significant decrease in 
IL-12 level in post-septic mice compared with sham-operated mice.  These findings 
indicated that pulmonary type-1 immune response might have been impaired by severe 
sepsis.  Given the importance of DCs in the initiation of the adaptive immune response 
and polarizing type-1 and type-2 response, we hypothesized that, in addition to impairing 
the recruitment of DCs into the lungs, severe sepsis also altered cytokine production by 
lung DCs.  After positive selection by CD11c microbeads, 90% of the purified DCs were 
alive established by trypan blue staining.  Given that lung macrophages have been 




Figure 3.5 Alteration of gene 
expression of IL-12p40 and 
IL-10 in DCs from post-
septic mice.  Sham and CLP-
operated mice (n=6-
8/group/time point) were 
subsequently intravenously 
challenged with 5,000 live S. 
mansoni eggs.  Eight and 16 
days later, mice were 
sacrificed and lung DCs were 
purified by positive selection 
with CD11c+ microbeads. 
After overnight culture, 
purified DCs (as shown in A) 
were stimulated with medium, 
80µg/ml SEA (TLR2 agonist), 
1µg/ml LPS (TLR4 agonist) 
or 2.5µg/ml Pam3cys (TLR2 
agonist).  Quantitative real-
time PCR was performed to 
measure the mRNA levels of 
IL-10 and IL-12p40 in 
cultured DCs after 6 hrs of 
stimulation.  * α, P≤0.05 
compared with IL-12p40 
mRNA level in the DCs from 
sham mice at days 8 and 16, respectively.  τ β, P≤0.05 compared with IL-10 mRNA level 
in the DCs from sham mice at days 8 and 16, respectively, after egg challenge. 
 
homogenously matched DC morphology (Fig 3.5A).  Ninety percent of these cells were 
CD11c+MHCII+ (data not shown).  When compared with DCs from sham mice, lung DCs 
from post-septic mice showed decreases of 4- and 7-fold in the baseline mRNA level of 
IL-12p40 at day 8 and day 16, respectively (Fig 3.5B and D medium).  In response to the 
stimulation with different Toll-like receptor (TLR) agonists [SEA (TLR2), LPS (TLR4) 
and Pam3Cys (TLR2)], lung DCs from post-septic mice contained significantly lower IL-
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12p40 mRNA level compared with DCs from sham mice (Fig 3.5B and D).  Conversely, 
lung DCs from post-septic mice exhibited a 2-fold increase in baseline mRNA level of 
IL-10 at both time points after egg challenge (Fig 3.5C and E medium).  Significantly 
higher IL-10 mRNA level in lung DCs was observed in post-septic mice compared with 
sham mice in response to LPS and Pam3Cys at both time points (Fig 3.5C and E).  The 
stimulation with SEA only induced a significant increase in IL-10 mRNA level in DCs 
from post-septic mice at day 8 post egg challenge. 
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Figure 3.6 DCs from post-septic mice show the defective IL-12p70 production and 
enhanced IL-10 production.  Sham and CLP-operated mice were sacrificed at days 8 
and 16 post egg challenge.  Lung DCs were purified by positive selection with CD11c+ 
microbeads from each animal.  After overnight culture, purified DCs were stimulated 
with medium, 80µg/ml SEA (TLR2 agonist), 1µg/ml LPS (TLR4 agonist) or 2.5µg/ml 
Pam3cys (TLR2 agonist).  ELISA was performed to measure the protein levels of IL-10 
and IL-12p70 in the supernatant of cultured DCs after 48 hrs of stimulation.  * α, P≤0.05 
compared with IL-12p70 level in the DCs from sham mice at days 8 and 16, respectively. 




           The protein levels of IL-12p70 and IL-10 in DC cultures were consistent with 
mRNA levels measured in DCs from sham and post-septic mice.  Specifically, DCs from 
post-septic mice produced lower amounts of IL-12p70 and higher amounts of IL-10 
constitutively and following TLR activation compared with DCs from sham mice (Fig 
3.6).  
IL-12 adenoviral vector restored the type-1 cytokine profile in post-septic mice 
            Having observed that post-septic mice had larger pulmonary granulomas and 
greater eosinophil recruitment when challenged with S. mansoni eggs, we next sought to 
determine whether this amplified granulomatous response could be altered by exogenous 
IL-12.  To increase IL-12 expression level in the lung, we utilized a transient IL-12 
transgene expression system whereby mice were administrated intratracheally a 
adenoviral vector containing the p35 and p40 cDNAs inserted into the E1 and E3 region 
of the viral genome, respectively.  Given that the E1 region of the viral genome has been 
deleted, this recombinant viral vector is replication deficient, resulting in transient 
expression of IL-12 in lung.  The peak concentration of IL-12 within the bronchoalveolar 
lavage fluid (BALF) was observed at day 1 after intratracheal administration of AdmIL-
12, followed by a gradual decrease through day 7 (254).  As shown in figure 3.7, there 
were lower IL-12p-70 protein level in the whole lungs from post-septic mice compared 
with sham mice in the control virus group at days 6 and 8, which is consistent with the 
observation shown in figure 3.3.  However, compared with Ad70 group, post-septic mice 
receiving the IL-12 vector showed a significant increase in the expression of IL-12p70 at 
day 6 (0.272±0.008 vs. 0.5±0.029 ng/mg total protein, n=4; p<0.001) and day 8 
(0.274±0.029 vs. 0.556±0.021 ng/mg total protein, n=6; p<0.001).  Although the IL-12 
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vector did not affect all the type-2 related cytokines, it did reduce IL-4 protein levels 
significantly at day 6 (0.141±0.009 vs. 0.032±0.004 ng/mg total protein, n=4; p<0.001).  
No changes in IL-5, IL-10 and IL-13 expression were observed in post-septic mice that 


























































Figure 3.7 Introduction of IL-12-expressing adenovirus reverses the type-2 biased 
cytokine profile in the post-septic lung.  Sham or post-septic mice (n=4-6/group/time 
point) were intratracheally administrated with 3X108 PFU IL-12 expressing adenovirus 
(AdmIL-12) or control adenovirus (Ad70) immediately followed by 5,000 S. mansoni 
eggs given intravenously.  At 6, 8 and 16 days after virus and egg challenge, mice were 
killed and the lower right lobes were collected from each mouse for cytokine analysis by 
ELISA.  The results shown are representative of two experiments and are expressed as 
mean ± SEM.  * P≤0.05 compared with IL-12p70 level in the lungs of sham mice 
receiving control virus at days 6 and 8.  α P≤0.05 compared with IL-12p70 level in the 
lungs of CLP mice receiving Ad70 at days 6 and 8.  β P≤0.05 compared with IL-4 protein 
level in the lungs of CLP mice receiving control virus at day 6. 
 
IL-12 adenoviral vector restored the altered pulmonary granulomatous response in 
post-septic mice, but did not influence DC recruitment to lung 
            We sought to determine whether the compartmentalized overexpression of IL-12 
influenced the alteration in granuloma size and eosinophil content in post-septic mice. 
Histological analysis showed that in Ad70 control groups, post-septic mice exhibited 
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significantly larger pulmonary granulomas than sham mice (30838.0±1166.4 µm2 vs. 
20713.6±1125.9 µm2, n=5; p<0.001) at day 16.  IL-12 vector significantly (p<0.001) 
decreased the granuloma size in post-septic mice compared with post-septic mice 
receiving Ad70 control virus (21792.3±1133.0 µm2 vs. 30838.0±1166.4 µm2, n=5; 
p<0.001) (Fig 3.8A).  Interestingly, the significant reduction in granuloma size in post-
septic mice induced by the IL-12 vector was also observed at days 6 and 8.  
Quantification of eosinophils showed that the IL-12 vector also significantly reduced 
eosinophil recruitment to post-septic lung granulomas at day 8 (0.322±0.023 vs. 
0.488±0.027/100 µm2, n=25; p<0.001) and day 16 (0.610±0.025 vs. 0.909±0.036/100 
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Figure 3.8 Introduction of IL-12-expressing adenovirus attenuates pulmonary 
granuloma pathology.  Sham or post-septic mice (n=4-6/group/time point) were 
intratracheally administrated with 3X108 PFU IL-12 expressing adenovirus (AdmIL-12) 
or control adenovirus (Ad70) immediately followed by 5,000 S. mansoni eggs given 
intravenously.  At 6, 8 and 16 days after virus and egg challenge, mice were killed and 
the left lobe was collected from each mouse for histological analysis.  (A) Quantification 
of granuloma size.  * P≤0.05 compared with granuloma size measured in sham mice 
receiving Ad70 at day 16 after egg challenge.  α P≤0.05 compared with CLP mice 
receiving Ad70 at all of three time points.  (B) Eosinophil number.  ** P≤0.05 compared 
with intragranulomatous eosinophil count in sham mice receiving Ad70 at days 8 and 16 
after egg challenge.  β P≤0.05 compared with intragranulomatous eosinophil count in 
CLP mice receiving Ad70. 
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            Finally, to determine whether the attenuation of granulomatous response induced 
by the administration of AdmIL-12 was due to alteration in DC recruitment into the lungs 
of post-septic mice, we investigated the influence of IL-12 overexpression on the 
pulmonary DC component.  Compared with post-septic mice receiving Ad70, post-septic 
mice receiving AdmIL-12 contained similar percentages of both DC subpopulations in 
the lung at day 8 post egg challenge, indicating that IL-12 overexpression did not 














Figure 3.9  Introduction of IL-12-expressing adenovirus fails to enhance DC 
recruitment to post-septic lung.  Post-septic mice (n=5/group) were intratracheally 
administrated with 3X108 PFU AdmIL-12 or Ad70 immediately followed by 5,000 S. 
mansoni eggs given intravenously.  Eight days later, lungs were harvested from both 
group and digested by collagenase IV.  The dispersed lung cells were stained as follows: 
CD11c+ in combination with CD11b+ or B220+, followed by flow cytometry analysis. 
  
Discussion 
            Although the diagnosis and treatment of sepsis during the acute phase of this 
disease remain clinically challenging, recent attention has been directed towards studying 
the long-term consequence of severe sepsis on the host immune activity.  It has been 
shown that patients who survive severe sepsis are at a higher risk for secondary infections, 
cancer, and other complications for up to 8 years after the septic episode (47, 48).  This 
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suggests that the initial sepsis episode results in a profound alteration to the host innate 
and adaptive immune responses.  Previously, our lab observed that post-septic mice were 
more susceptible to a pulmonary infection initiated by the fungal pathogen A. fumigatus 
(38).  In the present study, we explored the pulmonary adaptive immune response 
following severe sepsis using freshly isolated S. mansoni eggs to induce a pulmonary 
granulomatous response.  S. mansoni eggs promote the development of a type-2 biased 
pulmonary granuloma (144, 260), but this response is not lethal, even under an 
immunodeficient condition.  In the present study, post-septic mice exhibited significantly 
larger granulomas with a higher eosinophil content.  These histological findings in post-
septic mice coincided with significantly decreased whole lung IL-12 levels and 
significantly increased whole lung levels of IL-4, IL-10 and IL-13 compared with sham 
mice during the formation and maintenance of the granulomatous response.  Since DCs 
play a central role during adaptive immunity and can polarize a type-1 immune response 
through the production of IL-12 (132, 261), we hypothesized that the skewed adaptive 
response might have been a consequence of alterations in DC recruitment and/or DC 
phenotype.  Post-septic mice had lower percentages of two DC subpopulations: 
CD11c+CD11b+ DCs and CD11c+B220+ DCs in the lungs.  Also associated with changes 
in DC proportions, lung DC production of IL-12 was decreased whereas these cells 
produced much greater IL-10 in post-septic mice compared with DCs from sham mice.  
The importance of IL-12 to the pulmonary immune response was highlighted in 
subsequent experiments in which an IL-12 expressing adenovirus modulated the 
pulmonary granulomatous response to that typically observed in non-surgically 
manipulated mice.  Furthermore, the mechanism whereby IL-12 overexpression 
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attenuated the granulomatous response in lung seemed to be downstream of DC function 
rather than DC recruitment, since the impaired DC recruitment induced by severe sepsis 
was not reversed by AdmIL-12 administration.  
            The polymicrobial peritonitis induced by CLP surgery closely mimics the clinical 
course of abdominal sepsis, resulting in a systemic inflammatory response syndrome 
(SIRS) (222).  While the severity of sepsis depends on the number of punctures and the 
gauge (size) of needle, the CLP operation may lead to the formation of an intra-
abdominal abscess (32), which is considered to be a protective “walling-off” response of 
the host against bacterial (262).  In our system, we found that the localized inflammatory 
response in the peritoneal cavity was significantly decreased after three days post-CLP, 
evidenced by the normalized levels of inflammatory cytokines/chemokines (data not 
shown).  This suggested the termination of the acute phase of the peritonitis; however, 
there is the possibility of a chronic inflammatory response continuing at the original 
puncture lesion. 
            S. mansoni egg-induced granulomas require the efficient and sequential 
recruitment of a series of immune effecter cells, including macrophages (263), CD4+ T 
cells (264) and eosinophils (265).  These specific immune cells form a strong cellular 
barrier and sequester the S. mansoni eggs from the surrounding healthy tissue.  We and 
others have shown that the cytokine/chemokine network plays a central role in the 
recruitment and activation of immune cells around the eggs (255, 266).  IL-4 operates as 
the key cytokine driving the type-2 response (144, 267).  IL-5 induces the recruitment of 
eosinophils (144).  IL-13 is a key mediator in the fibrotic process during schistosomiasis 
(145).  Conversely, mice receiving exogenous IL-12 protein develop smaller pulmonary 
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and hepatic granulomas and exhibit less severe tissue fibrosis (154, 155).  In the present 
study, the defect in IL-12 expression in the lungs of post-septic mice was associated with 
the development of a larger pulmonary granuloma characterized by significantly greater 
eosinophil numbers.  In contrast, the administration of an IL-12 expressing gene vector 
attenuated the aggressive eosinophilic granulomatous response in post-septic mice.  This 
supports the concept that IL-12 is a negative regulator of granulomatous responses 
induced by S. mansoni eggs, probably by altering the type-1/type2 cytokine profile, as 
shown in the present study.  Although the increased expression of type-2 related 
cytokines IL-4, IL-5, IL-10, IL-13 in post-septic mice was observed early and not later 
during the granulomatous response, it appears that this early alteration in the cytokine 
profile has profound effects in progression of the granulomatous response.  The 
development of a type-1 immune response requires the dominance of type-1 over type-2 
cytokines, however the persistent impairment in IL-12 production in post-septic lungs 
appears to have resulted in the imbalance between the type-1 and type-2 response. 
             Several studies have focused on the recruitment and function of DCs in the 
granulomatous response, since the DC is a critical cell type linking the innate and 
adaptive immune response and the DC has the capacity to modulate type-1 or type-2 
immune responses (139-141).  Immature DCs capture antigen in the peripheral tissue and 
migrate to the draining lymph nodes (DLN), where they activate T-cells, and initiate the 
type-1 or type-2 immune response depending on the presence of IL-12 (132, 261) or IL-4 
(132), respectively.  Controversy surrounds the origin of DCs, as well as subsets and 
functional differences between subsets, despite considerable recent focus on DC biology.  
In the present study, two general DC subsets, myeloid (CD11c+CD11b+) and 
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plasmacytoid (CD11c+B220+) DCs were differentially measured (268), which have been 
reported to differ in TLR expression (269) and cytokine production in response to viral or 
bacterial infection (268).  We observed the decreased recruitment of both DC 
subpopulations, and a defect in IL-12 production by a mixed population of DCs.  With 
the development of pulmonary granulomas, local immunity typically proceeds to a type-2 
biased response from a Th0 lung environment (143).  However, in the post-septic lungs, 
the alteration in the recruitment of DCs combined with the alteration in their cytokine 
generation appeared to have accelerated the appearance and magnitude of the type-2 
cytokine profile.  This may be explained in part by the enhanced IL-10 production and 
impaired IL-12 production in pulmonary DCs from post-septic mice.  IL-10 is a 
pleiotropic immunomodulatory cytokine that regulates the development and function of 
immune cells.  IL-10 induces anergy in T cells by inhibiting the proliferation and 
cytokine production of these cells (270) and promotes the development of regulatory T 
cells (271).  In addition to its effect on suppressing inflammatory and type-1 response, 
IL-10 strongly inhibits DC maturation and down-regulates MHC class II expression and 
the capacity to produce IL-12 (272-274).  Also DC-derived IL-10 was required for the 
optimal development of type-2 cells in a DC transfer study (156).  The ability of IL-10 to 
inhibit the type-1 response and IL-12 production is well established, although the manner 
in which IL-10 achieves its regulatory function has not been identified yet (118).  
            Several studies have reported the loss of DCs in the spleen and lymph nodes of 
septic patients or animals with severe sepsis (57)4, (54)7(58).  In the present study, we 
found a similar loss of DCs in the lung, supporting the concept that severe sepsis results 
in the systemic loss of DCs, probably due to detrimental influence on DC development or 
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increased DC apoptosis.  We observed an altered cytokine production profile by lung 
DCs in post-septic mice, which was directly related to the exacerbation of S. mansoni 
egg-induced granulomatous response.  Although we did not investigate other functions of 
lung DCs, it is highly possible that severe sepsis also impairs antigen presentation by 
DCs.  The present study suggested that the altered cytokine production in pulmonary DCs 
induced by severe sepsis was due to an alteration in DC phenotype rather than differential 
recruitment of different DC subtypes (275), but further study of the role of DC subsets in 
the altered adaptive immune response in the post-septic lung is warranted.  Accordingly, 
the modulation of DC recruitment and/or function could be a potential therapeutic 
modality to restore normal adaptive immune response in post-septic hosts. 
              In summary, we examined the alteration in pulmonary adaptive immunity after a 
severe innate immune response (due to sepsis).  Following sepsis, a type-2 biased 
cytokine environment was observed in the lung leading to an accelerated granulomatous 
response characterized by augmented eosinophilia.  Severe sepsis resulted in decreased 
DC recruitment and alterations in IL-12 and IL-10 synthesis by these cells.  Interestingly 
this response was reversed by the artificial elevation of IL-12 in the post-septic lung.  
This study supports the concept that a biased type-2 cytokine profile in the lung is a 
major consequence of severe sepsis, which may account for the altered host immunity 
seen in post-septic patients.  Thus, restoring the cytokine balance in the post-septic lung 





Epigenetic regulation of dendritic cell-derived interleukin-12 production facilitates 
immunosuppression following severe sepsis 
Summary  
            A variety of alterations are known to occur in both clinical and experimental 
severe sepsis, including long-term immunosuppression.  We have identified that the 
production of interleukin (IL)-12 by dendritic cells (DCs) is chronically suppressed 
during experimental severe sepsis induced by cecal ligation and puncture (CLP), which 
persisted six weeks after CLP.  Using chromatin immunoprecipitation (ChIP) techniques, 
we have demonstrated that the deficiency in IL-12 production by post-septic DCs was 
accompanied by reciprocal changes in histone H3 lysine-4 trimethylation (H3K4me3) 
and histone H3 lysine-27 dimethylation (H3K27me2), as well as changes in cognate 
histone methyltransferase (HMT) complexes on both the Il12p35 and Il12p40 promoters.  
Interestingly, hyperacetylation of histone H3 on the Il12p35 promoter was also observed 
in post-septic splenic DCs and correlated with transcription repression.  The treatment 
with trichostatin A (TSA), a histone deacetylase (HDAC) inhibitor, significantly 
decreased IL-12 production by bone marrow-derived DCs generated from naïve mice.  
Furthermore, TSA in vivo treatment enhanced animal survival following CLP-induced 
severe sepsis.  Collectively, these data implicate histone modification enzymes in 
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suppressing DC-derived IL-12, which may provide one of the mechanisms of long-term 
immunosuppression subsequent to the septic response. 
 
Introduction 
            Severe sepsis is often characterized by an initially overwhelming systemic 
immune response syndrome in response to various etiologies, followed by a 
compensatory anti-inflammatory response syndrome (208).  One of the sequels to septic 
response is immunosuppression that is responsible for severe sepsis-induced morbidity 
and mortality.  Clinical records have clearly documented that patients who survive sepsis 
are more susceptible to secondary infections, cancer, and other complications long after 
being discharged from the intensive care unit (44).  Interestingly, an epidemiologic study 
found that 8 years after surviving severe sepsis only 20% of this cohort were still alive 
(48), suggesting that the initial septic response resulted in a profound alteration in the 
host’s innate and/or adaptive immune response.  Recent experimental investigations have 
been directed towards studying the immunoregulation following severe sepsis and have 
identified alterations in dendritic cell (DC) numbers and functions as a potential 
mechanism responsible for the long-term reduction of the host’s immune response (59). 
Furthermore, we have characterized DC-derived IL-12 as a key cytokine, which is 
significantly downregulated in post-septic animals.  This severe sepsis-dependent 
alteration in DC-derived IL-12 subsequently renders these animals susceptible to a 
secondary microbial challenge and induces an exacerbated Th2 cytokine response in 
response to an acquired immune event (39, 40).  
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            A growing body of evidence demonstrates that an epigenetic mechanism is 
involved in the regulation of gene expression during normal embryonic development 
(161, 165).  Mis-regulation of histone modifying enzymes is commonly found in many 
diseases such as cancer and autoimmune diseases (276, 277).  Among various histone 
modifications, methylation of histone H3 lysine-4 (H3K4) and H3K27 mediated by 
distinct histone methylmetransferase (HMT) complexes is highly correlated with 
transcription activation (278, 279) and repression (189), respectively.  Furthermore, 
histone acetylation generally leads to chromatin opening up and gene transcription (168), 
although there are data showing that several histone deacetylase (HDAC) inhibitors 
decrease the production of proinflammatory cytokines (280-282).  Both histone 
methylation and acetylation have been implicated in the development of immune system, 
especially in the differentiation and maintenance of Th1/Th2 memory cells (182).  These 
data indicate that histone modifications play pivotal roles in immune reactivity. However, 
since most of this evidence has been derived from investigations assessing T cell activity, 
it remains elusive as to whether these essential epigenetic regulators are involved in 
modulating DC function, given an essential role of DCs both in innate and adaptive 
immune response (72).  Using an experimental severe sepsis model induced by cecal 
ligation and puncture (CLP), we demonstrate that changes in histone methylation and 
acetylation correlate with long-term reduction in IL-12 production in splenic DCs.  In 
vitro treatment with trichostatin A (TSA), a HDAC inhibitor, decreased IL-12 production 
by bone marrow-derived DCs (BMDCs).  In vivo TSA treatment resulted in an enhanced 
animal survival following CLP-induced peritonitis.  Thus, these epigenetic changes are 
 
 81 
potentially important for the establishment of certain cellular memory, which is essential 
for long-term suppression of host immune system following severe sepsis. 
 
Materials and Methods 
Mice  
Female C57BL/6 mice and female Il10-/- (C57BL/6-Il10tm1Cgn) were purchased from 
Taconic Farms (Germantown, NY) and The Jackson Laboratory (Bar Harbor, ME), 
respectively.  These mice were housed under specific pathogen-free conditions at The 
Unit for Laboratory Animal Medicine of the University of Michigan and treated in 
accordance with the guidelines of the animal ethical committee. 
CLP  
Sham and CLP surgery was performed as described in Chapter 2.  
Isolation of splenic DCs 
Spleens were collected from sham or CLP groups day 11 or 6 weeks after surgery.  A 
sterile insert from 10 ml syringe was used to grind spleen tissue through 40 µM nylon 
membrane (BD Biosciences, San Jose, CA).  After lysing red blood cells (RBCs) with 
ammonium chloride buffer (150mM NH4Cl, 10mM NaHCO3, 1mM tetrasodium EDTA), 
cell suspensions were enriched with anti-CD11c magnetic beads (Miltenyi Biotek, 
Auburn, CA).  Briefly, the cells were resuspended in 400µl of buffer (1×PBS/0.5% BSA) 
containing 100µl of CD11c microbeads.  After a 15-min incubation at 4°C, free beads 
were washed away and the cells conjugated with beads were passed through MS+ 
columns for positive selection.  Purified DCs were counted on a hemocytometer and 
subsequently diluted at 2X106/ml.  The aliquots of 200µl containing these cells were 
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added to 96-well plates, and stimulated with a group of TLR agonists: 2.5µg/ml Pam3cys 
(EMC microcollections, Tubingen, Germany), 1µg/ml lipopolysaccharide (LPS from 
Escherichia coli 0111:B4; Sigma-Aldrich, St. Louis, MO), or 2µM mouse CpG-DNA 
(HyCult Biotechnololgy, Canton, MA).  After 6 hrs of stimulation, total RNA was 
isolated using Trizol reagent (Invitrogen, Carlsbad, CA) and quantitative Real-time PCR 
(Taqman) was performed to measure gene expression of inflammatory cytokines 
(Applied Biosystems, Foster City, CA).  After 24 hrs of stimulation, cell free supernatant 
from each sample was subject to ELISA to measure protein levels of inflammatory 
cytokines.  In the experiments neutralizing IL-10, 1 or 10 µg/ml polyclonal neutralizing 
anti-10 antibody (R&D systems, Rochester, MN) was used with goat IgG as control. 
Generation of mouse BMDCs 
BMDCs were generated as descried previously with modification (39).  Briefly, BM cells 
were flushed out from the femurs and tibias of naïve female C57BL/6 mice, and RBCs 
were lysed with ammonium chloride buffer.  Whole BM cells were then cultured in 
RPMI 1640 (Mediateck, Chestnut Hill, MA) supplemented with 10% fetal calf serum 
(Atlas Biologicals, Fort Collins, CO), 2 mM L-glutamine (Mediateck), 100 U/ml 
penicillin, 100 µg/ml Streptomycin (Gibco, Carlsbad, CA), 50 µg/ml gentamicin (Gibco), 
1 mM sodium pyruvate (HyClone, Logan, UT), 1Χ nonessential amino acids (Mediateck), 
50 µM 2-mercaptoethanol (Sigma) and 20 ng/ml recombinant murine granulocyte-
macrophage colony-stimulating factor (rmGM-CSF) (R&D systems).  Three days later, 5 
ml culture medium containing 10ng/ml rmGM-CSF was added into culture flask.  Non-
adherent cells were collected at day 6 of culture and then subject to positive selection 
with anti-CD11c magnetic microbeads (see above).  The cells were stimulated with 
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1µg/ml LPS in the absence or presence of TSA (Sigma) at a series of increasing 
concentrations. 
Messenger RNA decay assay 
BMDCs from C57BL/6 mice were stimulated with 1 µg/ml LPS alone.  Four hours later, 
5 µg/ml Actinomycin D (ActD from Sigma) was added into culture for 1 h to stop RNA 
synthesis, followed by further incubation for 0-3 h with TSA (10 ng/ml).  The remaining 
IL-12p35 mRNA level was measured by Taqman RT-PCR at different time points after 
incubation with ActD (0, 1, 2 and 3 h). 
In vivo TSA treatment 
TSA was dissolved in DMSO to prepare stock solution of 1 mg/ml, which was further 
diluted 10 times with saline in the time of in vivo injection.  Ten-week-old female 
C57BL/6 mice were treated with s.c. injection of TSA at 1mg/kg body weight daily for 1 
week.  The dose of TSA was based on published results with modification, which 
demonstrated significant inhibition of tumor growth and proinflammatory cytokine 
production (280, 283).  Control mice were injected with saline-diluted DMSO alone.  
There were no differences between TSA-treated and vehicle-treated mice in weight, food 
and water consumption.  CLP surgery with either 9 punctures or through and through 
puncture was performed and survival was monitored for 7 days following surgery. 
Quantitative Real-time PCR (Taqman) 
Analysis of transcripts with Taqman was performed as described in Chapter 2.  
Measurement of cytokine protein levels 
Concentrations of IL-10, IL-12p40 and IL-12p70 were measured in BMDCs and isolated 
splenic DCs cell culture supernatants using a Luminex Bio-Plex 200 system (Bio-Rad 
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Laboratories, Hercules, CA), according to manufacturer’s protocol.  Briefly, 96-well 
multiplex assay plate was coated with anti-mouse cytokine 3-plex conjugated beads (IL-
10, IL-12p40 and IL-12p70).  Plates were rinsed 2 times with wash buffer A and cell-free 
supernatants, as well as series diluted standard cytokine, were loaded and incubated for 
30 min in room temperature with gentle vortex.  After 3 washings, the biotinylated mouse 
cytokine 3-plex detection antibody was added for 30 min in room temperature with gentle 
vortex.  The plates were washed again and PE-conjugated streptavidin was added for 10 
min in room temperature with gentle vortex.  Plates were washed and read using luminx 
Bio-Plex 200 system plate reader.  Murine stock cytokines of known concentrations, 
which came together with kit, were used to generate the standard curves from which the 
cytokine concentrations present in the samples were calculated.  The threshold of each 
cytokine is 5 pg/ml. 
Chromatin immunoprecipitation (ChIP) assay 
The ChIP procedure was performed using an assay kit (Upstate, Charlottesville, VA) 
according to the manufacturer's instructions.  Briefly, 1X106 isolated splenic DCs or 
BMDCs were stimulated with 1 µg/ml LPS for 6 hrs in the absence or presence of TSA at 
a series of increasing concentrations.  DNA-protein structure was then cross-linked by 
1% (v/v) formaldehyde for 10 min at 37°C.  Cells were collected and lyzed in 400 µl 
SDS lysis buffer.  The resulting lysates was sonicated to obtain DNA fragments ranging 
from 200–1,000 bp using a Branson Sonifier 450 (VWR Scientific, West Chester, PA) 
under the following condition: 6 times for periods of 15 s each.  After centrifuge, the 
supernatant containing chromatin was diluted from which an aliquot (2% volume) was 
saved to indicate the input DNA in each sample.  The remaining chromatin fractions were 
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precleared with salmon sperm DNA/protein A agarose beads followed by 
immunoprecipitation with the following antibodies: anti–acetyl histone H3 (06-599; 
Upstate), anti–H3K4me3 (ab8580; Abcam, Cambridge, MA), anti–H3K27me2 (07-452; 
Upstate), anti–MLL, anti-WDR5 and anti-EED (Dr. Yali Dou) (279), anti-RbBP5 (A300-
109A; Bethyl Laboratories, Monttgomery, TX), or anti-SUZ12 (ab12073; Abcam) 
overnight at 4°C with gentle rotation.  Cross-linking was reversed for 4 h at 65°C and 
was followed by proteinase K digestion.  DNA was purified by standard phenol/ 
chloroform and ethanol precipitation, and subjected to real-time PCR. Primers for mouse 
Il12p35 promoters: forward, 5'- GGGACGGTCCCGAATCTC; reverse, 5'- 
GGTGGCGCTTTCGAATTAAC, primers for mouse Il12p40 promoter: forward, 5'- TT 
CCCCCAGAATGTTTTGACA; reverse 5'- TGATGGAAACCCAAAGTAGAAACTG.  
Statistical analysis 
Results were expressed as means ± SEM. Student’s t test and one-way ANOVA were 
used to detect statistical significance. 
 
Results 
Deficiency in IL-12 production by post-septic splenic DCs 
            DCs serve as sentinel at portals of pathogen entry and orchestra host innate and 
adaptive immunity against invading pathogens by the production of inflammatory 
cytokines and the subsequent presentation of antigen to naïve T cells in the draining 
lymph nodes (72).  One of the key cytokines that facilitates these important immune 
responses is IL-12, which is a heterodimeric inflammatory cytokine composed of an IL-
12p35 and IL-12p40 subunit (118).  Since IL-12 generated by DCs is the key molecule to 
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direct a type-1 immune response (132), we sought to determine whether severe sepsis 
altered the capacity of DCs to produce IL-12.  The polymicrobial peritonitis induced by 
cecal ligation and puncture (CLP) procedure closely mimics the clinical course of 
abdominal sepsis (32).  At day 11 after surgery, splenic DCs were purified from sham or 
CLP mice and stimulated with a series of toll-like receptor (TLR) agonists: Pam3Cys 
(TLR2), LPS (TLR4) or mouse CpG-DNA (TLR9).  Real-time PCR showed that post-
septic splenic DCs had significant lower mRNA levels of both Il12p35 and Il12p40, but 
higher mRNA level of regulatory cytokine Il10 compared with similarly treated sham 
splenic DCs (Fig 4.1A).  Consistently, post-septic DCs generated significantly lower 
protein level of IL-12p70, but higher protein level of IL-10 in response to the stimulation 
with TLR agonists in in vitro culture systems (Fig 4.1B).  Lung DCs isolated from day 11 
after CLP showed a similar deficiency in IL-12 production compared with lung DCs from 
sham mice (data not shown). 
            As a regulatory cytokine, IL-10 has been reported to directly inhibit IL-12 
production both in vivo and in vitro (129, 284).  To test the hypothesis that the deficiency 
in IL-12 production by post-septic DCs was due to excessive IL-10 production in culture 
system, two concentrations of specific anti-IL-10 antibody (1 and 10 µg/ml) were used to 
block IL-10 production by both sham and post-septic splenic DCs in response to LPS 
stimulation (Fig 4.1C left panel).  Although IL-12 production by sham DCs was 
increased in the presence of anti-IL-10 in a dose-dependent manner, IL-12 production by 
post-septic DCs was not rescued by anti-IL-10 (Fig 4.1C right panel), which suggested 
that the deficiency in IL-12 production by post-septic DCs was not due to excessive IL-




Figure 3.1 Impaired IL-12 production by splenic DCs day 11 following experimental 
peritonitis.  (A) Purified splenic DCs from septic or control mice day 11 after surgery 
were stimulated by a series of TLR agonists.  Messenger RNA levels of the two IL-12 
subunits and IL-10 were determined by Taqman.  (B) Protein levels of IL-12p70 and IL-
10 were measured by Bio-plex.  (C) Purified splenic DCs from septic or control mice day 
11 after surgery were stimulated by LPS, in the absence or presence of anti-IL-10 
antibody.  Protein levels of IL-12p70 and IL-10 were determined by Bio-plex.  Results in 
A, B and C represent three to five independent experiments and are expressed as mean ± 
SEM.  *, P ≤0.05 compared with cytokine levels measured in splenic DCs from sham 
mice. 
             
            We next determined whether the deficient phenotype in IL-12 production 
exhibited by post-septic DCs was preserved over time in animals surviving experimental 
sepsis.  In this set of studies, cytokine production by splenic DCs was determined 6 
weeks after sham and CLP procedures.  No difference in weight or behavior was 
observed between the two groups of mice at this time point.  However, splenic DCs 
recovered from post-septic mice showed significantly lower mRNA levels of Il12p35 and 
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Il12p40 and produced lower IL-12p70 protein level in response to TLR agonist 
stimulation compared with similarly treated control splenic DCs (Fig 4.2A and B).  No 
difference in IL-10 production was observed between sham and post-septic splenic DCs, 
which suggested that the deficiency in IL-12 production by post-septic DCs, at this time 

























































Figure 4.2  Long-term deficiency in IL-12 production by splenic DCs following 
experimental peritonitis.  (A) Purified splenic DCs from septic or control mice 6 weeks 
after surgery were stimulated by a series of TLR agonists.  Messenger RNA levels of the 
two IL-12 subunits and IL-10 were determined by Taqman.  (B) Protein levels of IL-
12p70 and IL-10 were measured by Bio-plex.  *, P ≤0.05 compared with cytokine levels 
measured in splenic DCs from sham mice. 
 
Altered histone modifications on Il12 promoters in post-septic splenic DCs 
            Histone H3K4 and K27 methylations are required for the establishment and 
maintenance of gene regulation status (177, 285).  Specifically, methylation of H3K4, 
mediated by MLL family histone methyltransferases (HMTs), is correlated with 



















Figure 4.3  Promoter sequence of Il12p35 and Il12p40 with consensus motifs for key 
transcription factors.  The positions of Taqman primers around promoter regions of 
Il12p35 and Il12p40 during ChIP experiments are indicated. 
  
silencing (182).  The long-term maintenance of the deficiency in IL-12 production 
prompted us to hypothesize that an epigenetic mechanism might be involved in this 
process.  We tested this hypothesis by chromatin immunoprecipitation (ChIP) assay using 
anti-H3K4 trimethylation (H3K4me3) and anti-H3K27 dimethylation (H3K27me2) 
antibodies.  Taqman primers were designed at the promoter regions of Il12p35 and 
Il12p40 around the essential binding sites for several key transcriptional factors, such as 
Pu.1, IFN Regulatory Factor (IRF) and κB (Fig 4.3).  We found that splenic DCs from 
control mice showed a relative high H3K4me3 and low H3K27me2 at both Il12p35 and 
Il12p40 promoters, indicating that both of these genes are surrounded by permissive 
chromatin structure and are poised for expression upon exposure to stimulus.  Conversely, 
splenic DCs at day 11 after CLP showed significantly decreased H3K4me3 and increased 
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H3K27me2 at Il12p35 and Il12p40 promoters, suggesting that the chromatin status was 
skewed towards a more repressive status after the CLP procedure (Fig 4.4A).  This is a 
long-term effect as the repressive chromatin environment is present at 6 weeks after CLP; 
significantly decreased H3K4me3 and increased H3K27me2 at both Il12p35 and Il12p40 
promoters were observed in post-septic splenic DCs (Fig 4.4B).  Thus, the altered status 
of H3K4 and H3K27 methylations at Il12p35 and Il12p40 promoters correlated well with 













































Figure 4.4 Alterations in histone H3 methylation and acetylation on Il12 promoters 
in post-septic splenic DCs.  Splenic DCs were isolated from sham and CLP mice at 
either day 11 (A) or 6 weeks (B) after surgery.  ChIP assay was performed to determine 
the histone H3 methyaltion and acetylation status at the promoter regions of Il12p35 and 
Il12p40, respectively.  The results shown are representative of two to three independent 
experiments and are expressed as mean ± SEM. * P≤0.05 compared with splenic DCs 
from sham mice. 
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Differential recruitment of core components of HMT complexes on Il12 promoters 
            We next explored the molecular mechanism whereby post-septic splenic DCs 
exhibited decreased H3K4me3 and increased H3K27me2 on Il12 promoters.  
Methylations at H3K4 and H3K27 sites are mainly mediated by MLL family H3K4 
methyltransferases and PRC2 complex, respectively (189, 278).  MLL family HMTs 
share common structures, which include the catalytic subunit, as well as several structural 
proteins including the WD40-repeat protein WDR5, RbBP5 and Ash2L (186, 187).  
PRC2 complex consists of the core components EZH2, Suppressor of Zeste 12 (SUZ12), 
and embryonic ectoderm development (EED) (189).  The activities of both MLL family 
HMTs and PRC2 require the interaction of the catalytic subunits with other components.  
To assess whether the alterations in histone methylation were the result of the altered 
recruitment or the complex integrity of MLL complex and/or PRC2 complex at Il12 
promoters, respectively, we performed ChIP assays using a series of antibodies directed 
against the core components of these two complexes.  Although there was no difference 
in MLL1 binding on H3K4 at Il12 promoters between post-septic splenic DCs and 
control DCs, the recruitment of WDR5 and RbBP5 on Il12 promoters were significantly 
decreased in post-septic DCs compared with sham DCs (Fig 4.5).  In contrast, the 
recruitment of EED and SUZ12 were significantly increased in post-septic DCs 
compared with sham DCs (Fig 4.5A).  EZH2 binding was not investigated, because of the 
lack of ChIP-grade antibody.  Thus, our data suggests that alterations in the levels of 
H3K4me3 and H3K27me2 are related to the inactivation of the corresponding complexes 


























































Figure 4.5 Altered recruitment of HMT complexes at Il12 promoters in post-septic 
splenic DCs.  Splenic DCs were isolated from sham and CLP mice at either day 11 (A) 
or 6 weeks (B) after surgery.  Using appropriate antibodies directed against the core 
components of the MLL and PRC2 complexes, recruitment of the core components to the 
promoter regions of Il12p35 and Il12p40 was determined by ChIP assay.  The results 
shown are representative of two to three independent experiments and are expressed as 
mean ± SEM.  * P≤0.05 compared with splenic DCs from sham mice. 
 
HDAC inhibitor downregulates Il12p35 gene transcription and IL-12p70 production 
            In addition to methylation, we also assessed the histone acetylation level in post-
septic DCs.  To our surprise, splenic DCs at either day 11 or 6 weeks after CLP exhibited 
enhanced histone acetylation on Il12 promoters compared with sham splenic DCs (Fig 
4.4), which was accompanied with the downregulation of the genes.  This result suggests 
that histone acetylation is associated with decreased IL-12 production by post-septic DCs, 






























































Figure 4.6 TSA-induced hyperacetylation of histone H3 is associated with 
downregulation of Il12p35 transcription and IL-12p70 production.  (A) Naïve 
BMDCs were stimulated with LPS, in the absence or presence of a series of increasing 
concentrations of TSA.  * P≤0.05 compared with H3 acetylation at Il12 promoters in 
LPS-stimulated BMDCs.  (B) Messenger RNA levels of Il12p35 and Il12p40 were 
measured by Taqman in LPS-stimulated BMDCs in the absence or presence of increasing 
concentrations of TSA.  τ P≤0.05 compared with Il12p35 mRNA level in LPS-stimulated 
BMDCs.  (C) Protein production of IL-12p70 and IL-12p40 by LPS-stimulated BMDCs 
were measured by Bio-plex ELISA, in the absence or presence of a series of increasing 
concentrations of TSA.  α P≤0.05 compared with IL-12p70 produced by LPS-stimulated 
BMDCs.  (D) BMDCs were stimulated with 1 µg/ml LPS for 4 h, then 5 µg/ml ActD was 
added into culture for 1 h to stop RNA synthesis, followed by further incubation for 0-3 h 
with TSA (10 ng/ml).  The remaining IL-12p35 mRNA level was measured by Taqman 
RT-PCR at 0, 1, 2 and 3 h after incubation with ActD.  The results shown represent three 
to five independent experiments and are expressed as mean ± SEM. 
  
transcription activation.  A similar observation was made showing that HDAC inhibitors 
(HDIs) downregulated IL-12 production both in vitro (286) and in vivo (280).  To further 
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understand the role of histone acetylation in IL-12 repression, we investigated the effects 
of an HDAC inhibitor on the transcription of two subunits of IL-12 in bone marrow-
derived DCs (BMDCs) generated from naïve mice.  Trichostatin A (TSA) is a broadly 
used HDI and induces hyperacetylation of histones.  A series of increasing concentrations 
of TSA were used to increase acetylation of histones in BMDCs in the presence of LPS 
stimulation.  We found that high concentrations of TSA (10 and 100 ng/ml), which did 
not alter cell viability, significantly increased histone H3 acetylation at both Il12p35 and 
Il12p40 promoters (Fig 4.6A); meanwhile, they efficiently abolished the LPS-induced 
increase in Il12p35 transcript and IL-12p70 protein production, but not Il12p40 gene 
transcription and translation (Fig 4.6B and C).  Messenger decay assay rules out the 
possibility that TSA-induced decrease in Il12p35 mRNA level in the presence of LPS 
stimulation was due to an increased mRNA degradation, since 10 ng/ml TSA did not alter 
the degradation rate of Il12p35 mRNA after the incubation of actinomycin D (ActD) (Fig 
4.6D).  In contrast, low concentrations of TSA (0.1 and 1 ng/ml) altered neither histone 
acetylation on Il12 promoters nor LPS-induced IL-12p40 and IL-12p70 protein 
production.  Interestingly, we observed a slight increase in Il12p35 transcript level in the 
presence of low concentrations of TSA (0.1 and 1 ng/ml) in a dose-dependent manner 
(Fig 4.6B).  We hypothesized that this was due to the downregulation of LPS-induced IL-
10 production by TSA in a dose-dependent manner (Fig 4.7A and B).  BMDCs generated 
from naïve WT or IL-10 deficient (Il10-/-) mice were stimulated with LPS in the absence 
or presence of a series of increasing concentrations of TSA.  Again, LPS-induced Il12p35 
mRNA level was slightly increased in the presence of low concentrations of TSA (0.1 
and 1 ng/ml).  However, this slight increase was completely abolished in similarly treated 
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Il10-/- BMDCs (Fig 4.7C), suggesting that slight increase in Il12p35 mRNA level in the 
presence of low concentrations of TSA was due to the downregulation of LPS-induced 
IL-10 production by TSA.  Thus, our data indicated that histone hyperacetylation on 
Il12p35 promoter induced by TSA decreased Il12p35 transcription and IL-12p70 
production.  The transcription and translation of Il12p40 were not influenced by histone 

























Figure 4.7 Effects of TSA on LPS-induced Il12p35 transcription and IL-10 
production by BMDCs.  (A) Naïve BMDCs were stimulated with LPS, in the absence or 
presence of a series of increasing concentrations of TSA.  Messenger RNA levels of Il10 
were measured by Taqman RT-PCR.  (B) Protein levels of IL-10 were measured by Bio-
plex.  (C) BMDCs generated from naïve WT and IL-10-/- mice were stimulated with LPS, 
in the absence or presence of a series of increasing concentrations of TSA.  Messenger 
RNA levels of Il12p35 were measured by Taqman RT-PCR. 
 
In vivo TSA treatment enhances animal survival in CLP-induced moderate sepsis 
The hallmark of acute phase of sepsis is an exacerbated production of inflammatory 
cytokines/chemokines, the so-called “cytokine storm”, resulting in multiple organ 
dysfunction and death (11).  Our observation that TSA treatment inhibits the production 
of proinflammatory cytokine IL-12, in conjunction with other reports with similar 
observations (280, 286), leads us to hypothesize that TSA treatment may rescue animals 
from CLP-induced mortality.  For a long time our group has observed that the severity of 
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sepsis could be controlled by needle size, number of punctures and antibiotics utilization.  
While CLP with 9 punctures results in severe sepsis, CLP with through and through 
puncture leads to moderate sepsis (data not shown).  Although TSA in vivo treatment 
failed to influence animal survival in severe sepsis model induced by CLP with 9 
punctures, animal survival rate in moderate sepsis induced by CLP with through and 
through puncture were significantly increased from 56% to 100% by TSA treatment (Fig 
4.8).  This observation suggests that TSA treatment cannot completely reverse cytokine 
storm in severe sepsis, and it requires other synergetic interventions to achieve clinical 
efficiency. 
CLP with through and
through puncture










CLP with 9 punctures








Figure 4.8 In vivo TSA treatment enhances animal survival in moderate sepsis.  
Mice were s.c. injected with TSA at 1mg/kg body weight daily for 1 week, and subjected 
to CLP surgery.  Similarly diluted DMSO was used as control.  CLP with 9 punctures 
was used to induce severe sepsis, and CLP with through and through puncture was used 
to induce moderate sepsis.  Animal survival was monitored for 7 days after surgery. 
 
Discussion 
            The initiation and maintenance of the septic response is dependent on ill-
understand cellular and molecular mechanisms.  In addition to a significant challenge of 
the diagnosis and treatment of sepsis during the acute phase of this disease, clinical 
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records have clearly documented a sustained anti-inflammatory or immunosuppressive 
state in patients who survive severe sepsis following the initial hyper-inflammatory 
response.  The “immunoparalysis” in septic patients is manifested by an inability to 
eradicate the primary infection and/or the development of new secondary infections (44).  
Thus, the initial episode of severe sepsis, characterized by a dysregulated inflammatory 
response, leads to long-lasting complications regarding how the host responds to and 
deals with subsequent challenges.  Although the depletion of immune cells such as DCs 
and lymphocytes due to extensive apoptosis has been related to long-term 
immunosuppression (50), it seems unlikely that the decrease in immune cell numbers is 
the only mechanism whereby septic hosts fail to mount an appropriate immune response, 
since we have observed a gradual restoration of immune cells after the initial apoptosis-
induced immune cell depletion.  Therefore, dysfunction of immune cells, probably 
delivered by to a long-term maintenance of abnormal gene expression pattern, is a 
potential mechanism worthy of extensive investigation.      
            Epigenetic mechanism of gene regulation has been well established to play an 
essential role in the maintenance of gene expression pattern during embryogenesis and 
cancer (161, 276).  The combination of individual histone modifications, catalyzed by 
several families of histone-modifying enzymes, form a “histone code” that constitutes an 
important epigenetic determinant of the transcriptional state (165, 166).  It has been 
recently proposed that histone modifications regulate gene expression pattern in immune 
system (182).  The chromatin remodeling events have been documented on the IFNγ 
promoter, Il4 locus (including Il5, Rad50, Il13 and Il4) and Il17 promoter during the 
differentiation of Th1, Th2 and Th17 memory T cells (182, 204).  LPS-tolerant 
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macrophages have been shown to exhibit the “repressive” histone modifications at the 
promoters of tolerizeable class of genes (205).  MLL, a HMT enzyme specific for H3K4 
methylation has been reported to be essential for the maintenance of memory Th2 cell 
response (203), while EZH2, a core component of polycomb repressive complex 2 
(PRC2), has been identified as an important molecule for the continuance of a Th1 
cytokine phenotype via silencing of the cytokines Il4 and Il13 (182, 200).  In contrast to 
this clear evidence showing epigenetic alterations in some specific conditions in the 
immune system, the signaling pathways leading to those epigenetic changes remain 
largely unexplored.  In memory T cells, the candidate pathways include T cell receptor 
and cytokine/cytokine receptor signaling pathways, whereas the signaling pathways or 
key molecules that mediate the long-term histone modifications on Il12 promoters in 
splenic DCs after the induction of severe sepsis remain to be elucidated.  Based on the 
fact that overwhelmed pathological infection and dysregulated cytokine storm are 
hallmarks of severe sepsis, it is reasonable to hypothesize that toll-like receptor signaling 
and cytokine/cytokine receptor signaling pathways are potential contributors to the 
epigenetic changes described herein, and these pathways are worthy of further 
investigation. 
            In the present study, we report for the first time an epigenetic mechanism of gene 
regulation via histone methylation and acetylation in DCs.  We characterized several 
histone modifications on various Il12 promoter regions as important long-term regulators 
for IL-12 production by splenic DCs after the induction of severe sepsis.  We postulate 
that these alterations might contribute to immunosuppression observed in post-septic 
animals and patients.  We have observed both H3K4me3 and H3K27me2 at Il12 
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promoters.  The existence of bivalent domains of H3K4me3 and H3K27me2 has recently 
been reported in embryonic stem cells (192) and in terminally differentiated T cells (287).  
It suggests that the relative ratio between these two marks determines transcription 
outcomes.  Consistently, a decreased ratio between H3K4me3 and H3K27me2 on the 
promoter regions of Il12p35 and Il12p40 was associated with downregulation of gene 
expression in post-septic splenic DCs in the present study.  Furthermore, the decreased 
ratio of H3K4me3 and H3K27me2 was a result of altered binding of cognate HMT 
complexes.  In addition to the changes in histone methylation, we also found that post-
septic DCs exhibited enhanced histone acetylation at Il12 promoters.  Although histone 
hyperacetylation mostly correlates with gene activation, our data showed that 
pharmacological induction of histone hyperacetylations on the Il12p35 promoter resulted 
in decreased Il12p35 transcription and IL-12p70 production in BMDCs.  Given a recent 
report that H3K4me3 can be recognized by both HDAC and histone acetyltransferase 
(HAT), the observed hyperacetylation during gene activation is likely due to the 
decreased recruitment of HDACs upon H3K4 trimethylation (196).  The mechanisms that 





Severe sepsis-induced dysfunction in DC: T cell interactions 
Summary  
            Severe sepsis has been defined as a systemic inflammatory disorder represented 
by an initial uncontrolled inflammatory response.  Clinical and experimental studies have 
shown that the acute phase of severe sepsis is followed by a chronic immunosuppression 
phase.  While all the mechanisms that contribute to the long-lasting immunosuppression 
are not clear, it is known that tissue dendritic cells (DCs) are initially depleted during the 
early stage of severe sepsis via apoptotic mechanism, but are subsequently repopulated.  
Interestingly, the repopulated DCs appear to have significant alterations that contribute to 
the persistent state of immunosuppressioin.  We now show that in addition to aberrant 
cytokine production (chapter 3 and 4), post-septic DCs exhibit an impaired antigen-
presenting capacity in co-culture with T cells.  T cells cultured with DCs recovered from 
surviving septic animals generate significantly higher levels of T helper 2 (Th2) 
cytokines, but lower level of interferon-γ (IFN-γ) compared to sham DCs, indicating that 
post-septic DCs have a Th2-polarized capacity.  Using microarray analysis followed by 
Taqman, we identified a dramatic upregulation of a cysteine proteases inhibitor (stefin 
A1) in bone marrow, lung and splenic DCs from animals that survive severe sepsis, 
which potentially may contribute to the sepsis-induced DC defect in antigen-presenting 
function.  These data further indicate that severe sepsis results in an additional DC 
 
 101 




            The clinical manifestations of sepsis are usually the initial consequence of a 
dysregulated host immune response to either a known or uncharacterized insult (9, 45).  
Despite advances in intensive care technology and mechanical ventilator support, 
efficacious pharmacologic options are limited (17).  In addition, epidemiologic studies 
have demonstrated that patients who survive severe sepsis have a significant risk of dying 
that exceeded normal predictions for several years after recovering from severe sepsis (47, 
48).  These patients were shown to be more susceptible to secondary infections, cancer, 
and other complications long after being discharged from the intensive care unit (47, 48). 
Therefore, these investigations suggest that the initial episode of severe sepsis results in a 
profound alteration in the host’s innate and/or adaptive immune response.  
            Recent experimental investigations studying the immunoregulation following a 
severe innate immune response due to sepsis have identified alterations in DC number 
and function as potential mechanisms for the long-term alteration in the host’s immune 
response (59).  We have previously characterized DC-derived IL-12 as a key host defense 
cytokine that is significantly downregulated even 6 weeks after the original septic event, 
which was associated with epigenetic changes at the Il12 promoters (chapter 4).  This 
sepsis-dependent alteration in DC-derived IL-12 has been shown to render animals 
susceptible to a secondary microbial challenge and induces an exacerbated Th2 cytokine 
response in response to an acquired immune event (39, 40).  However, in the context of 
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severe sepsis, the antigen (Ag)-presenting function of DCs, which is essential for the 
initiation of host adaptive immune response, has not been thoroughly investigated. 
            Adaptive immune responses are initiated in the T cell-zones of secondary 
lymphoid organs, where naïve T cells encounter antigen-bearing mature DCs (72).  In 
order to present antigen to T cell receptor (TCR)-specific naïve T cells, the DCs 
phagocytose and degrade the antigen into optimal peptides (antigenic epitopes), but 
complete destruction of the antigen by endosomal/phagosomal processing enzymes is 
avoided (288).  The efficient formation of MHCII-peptide complex in late endosome 
requires endosomal/phagosomal proteolysis both to generate suitable peptides and to 
remove the dedicated class II MHC chaperone invariant chain (Ii) (289).  These processes 
are tightly regulated by a family of lysosomal cysteine proteases (cathepsins) (290).  
Within this set of enzymes, cathepsin S appears to be the major protease involved in Ii 
degradation and is one of the major endoproteases involved in Ag-processing outside of 
the thymus (291, 292).  Meanwhile, the enzyme activity of cathepsin S is regulated by its 
endogenous inhibitor stefin A (Stfa), which belongs to a large superfamily of highly 
conserved proteins that act as potent inhibitors of endosomal cathepsins (293) and has 
been genetically linked to day 3 thymectomy (D3Tx)-induced antoimmune ovarian 
dysgenesis (AOD) (294).  Interestingly, cathepsin S has been reported to be involved in 
D3Tx-induced antoimmune disease of the salivary and lacrimal glands (295).  Therefore, 
the abnormal expression and effects of cathepsins or stefin A may contribute to the 
alteration in the host adaptive immune response, resulting in either immunoamplification 
or immunodeficiency.    
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            In the present study, we observed that after severe sepsis, splenic DCs exhibited 
an impaired Ag-presenting function and Th2-polarized capacity during the interaction 
with TCR-specific T cells.  Interestingly, dramatic and long-term upregulation of stefin 
A1 was observed in bone marrow, splenic DCs and lung DCs after animals had survived 
severe sepsis.  This correlation suggests that overexpression of stefin A1 in tissue DCs 
induced by severe sepsis enhances its inhibitory effect on cathepsin S and DC Ag-
presenting function, which subsequently contributes to the immnosupression observed in 
septic patients and experimental septic animals.     
 
Materials and Methods 
Mice  
Female C57BL/6 mice (6-8 wks; Taconic Company, Germantown, NY) and OVA-
specific TCR-transgenic OT II mice (The Jackson Laboratory, Bar Harbor, ME) were 
housed under specific pathogen-free conditions at The Unit for Laboratory Animal 
Medicine (ULAM) of the University of Michigan. The University Committee for the 
Using and Care of Animals (UCUCA) approved the experiments. 
Cecal ligation and puncture (CLP)  
Sham and CLP surgery was performed as described in Chapter 2.  
Isolation of lung and splenic DCs 
Isolation of lung DCs and splenic DCs were performed as described in Chapter 3 and 4.  
cDNA Microarray 
DNA microarray analysis of gene expression in total BM cells was done as previously 
described (296).  Briefly, BM cells were flushed from the femurs and tibias and total 
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RNA was isolated using Trizol Reagent.  Isolated RNA (20 µg) was used as a template 
for cDNA generation using reverse transcriptase (Invitrogen, Carlsbad, CA) in the 
present of amino allyl-dUTP (Sigma, St. Louis, MO) that allow for subsequent 
fluorescent labeling of cDNA using Cy3 or Cy5 NHS ester dyes (Amersham Pharmacia 
Biotech Ltd., Buckinghamshire, UK).  The cDNA from each time point-matched control 
sample was labeled with fluorescence dye Cy3 and the experimental sample with Cy5.  
The labeled probes were then hybridized to mouse cDNA microarray (Mouse M22.4K1; 
University Health Network Microarray Center, Toronto, Canada) at 65°C overnight.  
RNA samples from a total of three mice at each time point were analyzed separately by 
three individual chips (one for each rat sample).  Fluorescent images were obtained using 
a GenePix 4000B microarray scanner (Axon Instruments, Foster City, CA).  Primary 
analysis was performed by using the GenePix software package (Axon Instruments).  
Cy3 to Cy5 ratios were determined for the individual genes along with various other 
quality control parameters, i.e., intensity over local background.  The average median 
ratio values for all spots were normalized to 1.0. The data set was imported into Cluster 
Analysis of Gene Expression Dynamics (CAGED).  CAGED v1.0 software is designed to 
perform Bayesian model-based clustering on temporal gene expression data (297).  
Quantitative Real-time PCR (Taqman) 
For quantitative mRNA analysis, total RNA was isolated from total BM cells, purified 
lung DCs and splenic DCs.  Primer Express 2.0 software (Applied Biosystems, Foster 
City, CA) was used to design Taqman primers for stefin A1 (Stfa1), which were then 
purchased from Sigma-Genosys (The Woodlands, TX).  Primers for stefin A1 were as 
follows: forward, 5′- AACCTGCCACACCAGAAATCC; reverse, 5′- 
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TTCTTATTGGTTTTTGCTTCAAGCT.  GAPDH was analyzed as an internal control.  
Analysis of transcripts with Taqman was performed as described in Chapter 2.  
Antigen-presenting and Th1/Th2-polarizing capacity assay 
Splenic DCs were isolated from sham or CLP mice at day 11 after surgical operation 
(described above), and pulsed with 5 µg/ml OVA323-339 peptides (Peptides International, 
Inc., Louisville, KY) for 4 hours.  After removing soluble OVA323-339 peptide in the 
medium, CD4+ T cells isolated from spleens of naïve OT II mice with anti-CD4 magnetic 
beads (Miltenyi Biotech, Auburn, CA) were added to the DC culture.  After 24 hours, 
supernatants were collected and stored in -80°C until measurement of protein levels of 
IL-4, IL-5, IL-13 and IFN-γ by ELISA.  In a parallel experiment, three days after co-
culture between OVA323-339-pulsed DC and OVA323-339-specific CD4+ T cells, T cell 
proliferation was measured by the incorporation of [3H]-thymidine with a multi-purpose 
scintillation counter (Beckman Coulter, Fullerton, CA). 
            In another set of experiments using Schistosoma mansoni egg antigen (SEA), 
splenic DCs isolated from sham or CLP mice day 11 after surgical operation were pulsed 
with 10 µg/ml SEA for 4 hours (40).  Splenic CD4+ T cells were isolated with anti-CD4 
magnetic beads (Miltenyi Biotech) from mice that had been immunized with 3,000 live S. 
mansoni eggs for 2 weeks, and added to the SEA-pulsed DC culture.  After 24 hours, 
supernatants were collected for the measurement of protein levels of IL-4, IL-5, IL-13 
and IFN-γ by ELISA.  After 3 days, T cell proliferation was measured by the 
incorporation of [3H]-thymidine. 
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Flow cytometry analysis 
At day 3 or day 11 after CLP, spleens were collected from sham and CLP mice and 
dispersed in 0.2 % collagenase (Sigma-Aldrich, St. Louis, MO) in RPMI 1640 
(Mediateck, Inc., Herndon, VA) at 37°C for 30 min.  After lysing red blood cells, Fc 
binding was blocked via a 10-min incubation with purified rat anti-mouse CD16/CD32 
(FcγIII/II receptor).  Then the cells were stained with FITC-labeled anti-CD11c in 
combination with each of the following antibodies: PE-anti-CD40, PE-anti-CD80, PE-
anti-CD86, or PE-anti-I-Ab in Dulbeco’s PBS + 0.2% BSA + 0.1% NaN3 for 30 min at 
4°C in the dark.  The appropriate IgG isotypes were used as controls.  All antibodies and 
IgG isotypes were purchased from BD PharMingen (San Diego, CA).  The cells were 
fixed in 1% paraformaldehyde and kept in the dark at 4°C until analysis with a 
FACSCaliber (CELLQuestTM software; Becton and Dickinson, Mountain View, CA). 
Statistical analysis 
Student’s t test and one-way ANOVA were used to detect statistical significance. 
 
Results and Discussion 
Impaired antigen-presenting function of post-septic splenic DCs 
            DCs have an essential role in both the innate and adaptive immune response via 
their unique functions, including cytokine production and Ag-presenting activities (72, 
89).  Our previous data showed that severe sepsis resulted in a long-term deficiency in 
IL-12 production by DCs, which was associated with epigenetic alterations (chapter 4).  
This observation is consistent with the susceptibility of post-septic mice to a secondary 
challenge with Aspergillus fumigatus, as an intact host innate immune response with a 
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robust IL-12 production is required to clear this normally innocuous fungus challenge (38, 
39).  This data underscores the notion that defective cytokine production by DCs impairs 
the host innate immunity.  Furthermore, we have shown that post-septic mice exhibited 
an altered granulomatous response to a secondary challenge with S. mansoni eggs, which 
is known to induce a cell-mediated Th2-skewed immune response (chapter 3); thus, we 
hypothesized that severe sepsis impairs DC Ag-presenting function.  OVA peptide-
specific CD4+ T cells isolated from TCR transgenic OT II mice were employed to study 
DC Ag-presenting function following experimental peritonitis.  At day 11 after CLP, 
CD4+ T cells were observed to proliferate at a significantly lower rate in co-culture with 
OVA323-339-pulsed splenic DCs isoloated from post-septic mice, as compared with CD4+ 
T cells in co-culture with similar treated splenic DCs from sham mice, indicating that 
severe sepsis results in an impaired DC Ag-presenting function (Fig 5.1A). 
            Although SEA fails to induce the “classical” maturation of DCs, including the 
upregulation of CD40, CD80, CD86 and MHCII molecule, DCs have been shown to be 
able to present SEA to naïve T cells and induce SEA-specific Th2 response (147, 152).  
To confirm the observation from the above Ag-presenting assay using OVA peptide, we 
also utilized SEA-pulsed DCs to induce the proliferation of CD4+ T cells obtained from 
mice sensitized with SEA.  At day 11 after CLP, CD4+ T cells proliferated with a 
significantly lower rate in co-culture with SEA-pulsed post-septic splenic DCs, as 
compared with CD4+ T cells in co-culture with similar treated sham splenic DCs (Fig 
5.1B).  Thus, data from experiments using different antigens suggest that severe sepsis 
results in an impaired DC Ag-presenting function. 
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Figure 4.1 Impaired antigen-presenting function of post-septic splenic DCs.  (A) 
Purified splenic DCs from post-septic or control mice day 11 after surgery were pulsed 
with 5 µg/ml OVA323-339 peptide, and co-cultured with splenic CD4+ T cells isolated from 
naïve TCR transgenic OT II mice.  Seventy-two hours later, 1 µCi  [3H]-thymidine was 
added to the DC: T cells co-culture for 6 hrs.  T cell proliferation rate was measured by a 
multi-purpose scintillation counter.  (B) Purified splenic DCs from sham or CLP day 11 
after surgery were pulsed with 10 µg/ml SEA, and co-cultured with splenic CD4+ T cells 
isolated from mice sensitized with 3,000 live S. mansoni eggs.  T cell proliferation was 
measured by the incorporation of [3H]-thymidine.  *, P ≤0.05 compared to CD4+ T cell 
[3H]-thymidine incorporation in co-culture with sham splenic DCs. 
 
            It has been well established that DC Ag-presenting function is determined by 
three signals, including MHCII-peptide complex, co-stimulatory molecules expressed on 
the cell surface of DC and T cells, and the cytokine environment (113).  To determine if 
there is any alteration in co-stimulatory molecule expression that might influence DC Ag-
presenting capacity in septic mice, we measured the expression levels of co-stimulatory 
molecules, including CD40, CD80 and CD86, as well as MHCII molecule, on DC cell 
surface following experimental peritonitis.  At day 11 after CLP, there was no difference 
in the expression of any of these molecules, indicating that the impaired Ag-presenting 
function of post-septic DCs was not due to the effects of co-stimulatory molecules (Fig 
5.2B).  Similar observations were made when we measured the expression levels of co-
stimulatory and MHCII molecules on DC cell surface at 6 weeks after CLP (data now 
shown).  Interestingly, we observed increased expression of CD40, CD80 and CD86 on 
 
 109 
splenic DC cell surface at day 3 after CLP, presumably reflecting the activated DC 
phenotype associated with systemic inflammatory immune response in the acute phase of 
severe sepsis (59) (Fig 5.2A).  
 
Figure 5.2 Expression of 
costimulatory and MHCII 
molecules on DC cell surface 
following severe sepsis.  Spleens 
were collected and dispersed from 
sham and CLP mice at day 3 (A) or 
day 11 (B) after CLP.  Expression of 
CD40, CD80, CD86 and MHCII were 
investigated on cell surface of 
CD11c+ DCs.  Black line, isotype 
control; dotted line, sham group; red 










Dramatic increase in stefin A1 expression in bone marrow and tissue DCs following 
severe sepsis   
            When we compared the global gene expression pattern in total BM cells between 





A1 (Stfa1) that was dramatically upregulated in septic mice at day 11 after CLP.  Three 
individual hybridizations showed that there was a 4-fold increase in Stfa1 transcript level 
in post-septic BM cells, as compared to sham BM cells (Fig 5.3A).  Stefin A1 has been 
identified to be an intracellular inhibitor of cysteine proteinases (cathepsins) (293), 
including cathepsin S (294).  Cathepsin S is the major protease involved in Ii degradation 
and therefore plays an essential role in the formation of MHCII-peptide complex during 
MHCII-restricted Ag-presentation process in DCs (289).  Thus, stefin A1 appears to 
inhibit DC Ag-presenting function via its inhibitory effect on cathepsin S.  We 
hypothesized that the upregulation of stefin A1 induced by severe sepsis could 
compromise DC Ag-presenting function.  We utilized RT-PCR to measure Stfa1 
transcript level in tissue DCs following severe sepsis.  At day 11 after CLP, post-septic 
splenic DCs had significantly higher mRNA level of Stfa1 in response to either medium 
or series of TLR agonists (Pam3Cys for TLR2, LPS for TLR4, CpG for TLR9) (Fig 
5.3C).  The upregulation of Stfa1 is a long-term consequence of severe sepsis, since post-
septic splenic DCs maintained a higher Stfa1 mRNA level six weeks after CLP (Fig 
5.3D).  Interestingly, total BM cells also contained significantly higher Stfa1 mRNA level 
out to 19 days post CLP (Fig 5.3B).  Furthermore, Stfa1 mRNA levels were dramatically 
induced in lung DCs from post-septic mice at day 11 or 6 weeks after CLP, although 
there was no detectable Stfa1 mRNA in lung DCs from sham mice, indicating severe 
sepsis-induced stefin A1 upregulation is common to tissue DCs.  Our observations 
suggest that severe sepsis promotes the expression of stefin A1 in tissue DCs, which may 
subsequently enhanced its inhibitory effect on cathepsins and Ag-presenting function of 
post-septic DCs.  Further investigations are required to study the role of stefin A1 on DC 
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Figure 5.3 Stefin A1 expression in bone marrow and tissue DCs following severe 
sepsis.  (A) Total BM cells were flushed from femors and tibias day 11 after CLP. 
Upregulation of stefin A1 in BM cells following severe sepsis was identified by cDNA 
microarray analysis.  (B) Messenger RNA levels of Stfa1 in total BM cells at different 
time points after CLP were determined by Taqman.  (C) Purified splenic DCs from septic 
or control mice day 11 after surgery were stimulated by series of TLR agonists.  
Messenger RNA levels of Stfa1 in splenic DCs were determined by Taqman.  (D) 
Purified splenic DCs from septic or control mice 6 weeks after CLP were stimulated by 
series of TLR agonists and mRNA levels of Stfa1 were determined by Taqman.  Results 
in B, C and D represent two to four independent experiments and are expressed as mean 
± SEM.  *, P ≤0.05 compared with Stfa1 transcript levels measured in sham mice. 
 
Ag-presentation in the context of severe sepsis and may provide insight into the 
development of new therapeutic strategies for dysfunctional DCs and 
immunosuppression observed in septic patients.  
Th2-polarized capacity of post-septic splenic DCs  
            When challenged with S. mansoni eggs, post-septic mice showed an enhanced 
Th2 cytokine profile and an exacerbated Th2 cells-mediated granulomatous response 
(chapter 3).  Therefore, we hypothesized that after severe sepsis, Ag-loaded DCs directs 
naïve T cells towards a Th2-baised response.  Splenic DCs recovered from day 11 post-
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septic mice were pulsed with OVA peptide and co-cultured with OVA peptide-specific 
CD4+ T cells isolated from TCR transgenic OT II mice.  These T cells generated 
significantly higher levels of Th2 cytokines such as IL-4, IL5 and IL-13, but lower level 
of Th1 cytokine IFN-γ, as compared to similar co-culture using splenic DCs from sham 
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Figure 5.4 Th2-polarized capacity of post-septic splenic DCs.  (A) Purified splenic 
DCs from post-septic or control mice day 11 after surgery were pulsed with 5 µg/ml 
OVA323-339 peptide, and co-cultured with splenic CD4+ T cells isolated from naïve TCR 
transgenic OT II mice.  Twenty-four hours later, the supernatants were collected to 
measure cytokine protein levels by Bio-Plex.  (B) Purified splenic DCs from sham or 
CLP day 11 after surgery were pulsed with 10 µg/ml SEA, and co-cultured with splenic 
CD4+ T cells isolated from mice sensitized with 3,000 live S. mansoni eggs.  Twenty-four 
hours later, the supernatants were collected to measure cytokine protein levels by Bio-
Plex.  Results represent 3 independent experiments and are expressed as mean ± SEM.  *, 
P ≤0.05 compared to cytokine protein levels in the supernatants of co-culture between 
CD4+ T cells and sham splenic DCs. 
 
            We further studied Th1/Th2 polarizing function of post-septic DCs pulsed with 
SEA and co-cultured with CD4+ T cells that were obtained from the mice sensitized with 
SEA for 2 weeks.  These CD4+ T cells also generated significantly higher levels of Th2 
cytokines such as IL-4, IL-5 and IL-13, but lower level of Th1 cytokine IFN-γ, as 
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compared with in co-culture with similar treated sham splenic DCs (Fig 5.4B).  Taken 
together, our data suggest that post-septic DCs induce a Th2-polarized effect on T cells, 
which may provide a cytokine environment that renders the host susceptibility to a 
secondary pathological challenge that would require an intact Th1 immune response. 
            In addition to aberrant cytokine production, DCs also demonstrate an impaired 
Ag-presenting function and capacity to polarize T cells to a Th2 phenotype following 
severe sepsis.  These deficiencies likely impair both the innate and adaptive immune 
response of the host, which is manifested by clinical reports showing that patients who 
survive sepsis are at a significant risk of dying due to secondary pathological infections 
and cancer for years after the initial severe septic event (44, 45, 47, 48).  Since we 
characterized epigenetic mechanisms involved in long-term deficiency in IL-12 
production by post-septic mice, one intriguing hypothesis is that the impaired Ag-
presenting function and Th2-polarized capacity of post-septic DC are mediated by long-
term aberrant expression of some key molecules, which also involves epigenetic 
alterations.  Stefin A1 is a candidate molecule, since we observed that upregulation of 
Stfa1 transcript was maintained long-term and stefin A1 is a potential regulator of DC 
Ag-presenting function.  Therefore, genome-wide analysis of epigenetic changes at 
promoter regions in DCs following severe sepsis by ChIP-chip technique, in conjunction 
with global comparison of gene expression pattern between sham and post-septic DCs by 
microarray will improve our understanding of molecular mechanisms of DC dysfunction 
and immunosuppression, and facilitate the development of new therapeutic strategies for 




Conclusions and future directions 
            The general consensus of recent investigations is that the acute inflammatory 
response is tightly linked to innate immunity, which usually occurs over a relatively short 
time period.  During this limited time frame, a functional acute inflammatory response is 
supported by the temporal expression of a set of inflammatory mediators and activation 
of specific leukocyte subpopulations.  For example, within the first hour of an in vivo 
LPS challenge, mRNA expression for early response cytokines such as TNF-α can be 
detected in mononuclear phagocytic cells followed by the expression of secondary 
response cytokines and chemokines (298, 299).  Interestingly, the quantity and 
complexity of the initial antigen or pathogen determine the severity and duration of acute 
inflammatory responses (249, 300).  An additional factor that determines the clinical 
course of an acute inflammatory response is the rigor of the host’s immune response to 
the inciting agent (48, 301).  An interesting inverse clinical correlation exists between the 
severity of the initial acute inflammatory response and the ability of the host to deal with 
a subsequent immune challenge months later, indicating an important role of the initial 
acute response in shaping the host’s response to a subsequent challenge (5, 47, 48).  
            The chronic consequences linked to severe acute inflammation have been found 
in many severe acute human diseases, including the acute ischemia/reperfusion injury 
post organ transplant (302), severe respiratory syncial viral infection in neonates (303, 
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304), and severe burn and trauma injury (305, 306).  Many of these clinical cases appear 
to be governed by severe, life-threatening inflammatory events, followed by a long 
lasting improper or immunosuppressed immune response.  One of the best examples of 
the chronic effects of severe acute inflammation is severe sepsis, both in patients and in 
experimental animal models.  Several studies have noted that the septic population has an 
increased risk of dying for many years after the initial hospitalization (47, 48). Following 
the initial hyperinflammatory response, septic patients develop a sustained anti-
inflammatory or immunosuppressive state that has been termed “immunoparalysis”, 
which is manifested by an inability to eradicate the primary infection and/or the 
development of new secondary infections (41-46).  Many of the pathogens responsible 
for the secondary, hospital-acquired infections are not particularly pathological in 
patients with competent immune systems, indicating the immunosuppressive state of 
patients with severe sepsis.  Thus, the initial episode of severe sepsis, characterized by a 
dysregulated inflammatory response, appears to lead to long-lasting complications 
regarding the manner in which the host responds to and deals with subsequent challenges.  
In the present study, we modeled the long-term immunosuppression after severe sepsis 
using a CLP sepsis animal model and characterized the DC alterations in cytokine 
production and Ag-presenting functions.  Our studies generated 3 additional questions 
that will be discussed below. 
            There is little doubt that DCs, although small in number, play a large role in 
maintaining an appropriate and protective innate and acquired host response.  Therefore, 
DCs are logical participants in the initial severe infection and dysregulated cytokine 
storm in the early stage of severe sepsis.  Indeed, DCs undergo a rapid depletion in septic 
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patients (54) and in experimental sepsis animal models (55-59).  We observed an initial 
dramatic depletion of both mDC and pDC in peripheral organs at the early stage of severe 
sepsis (Fig 1.2), which was consistent with previous reports.  In addition, DC populations 
are gradually reseeded to the distant organs, as their numbers gradually return to normal 
levels after a significant recovery period (Fig 1.2).  The first question we would like to 
address in future studies is:  Where does the generation of DCs occur post sepsis?  It is 
possible that after sepsis DCs are newly generated in BM, and migrate to peripheral sites 
via the action of chemokines (233).  Evidence supporting this hypothesis is from the 
study showing that experimental peritonitis induced by colon ascendens stent peritonitis 
(CASP), another common procedure to induce severe sepsis (32), significantly enhances 
cell proliferation in BM and promotes colony formation by granulocytic-monocytic 
precursors (307).  An alternative possibility is that DCs are generated in peripheral sites 
from precursor cells, which have been recruited into the periphery during the acute 
inflammatory response.  It is important to answer these questions, since normal 
hematopoiesis is influenced by the surrounding tissue microenvironment (hematopoietic 
niche) (308, 309).  The tissue location in which DCs are generated will definitely 
contribute to the final DC phenotype and direct the properties of the newly generated 
DCs.  Future studies, monitoring the migration of HSCs between BM and peripheral sites 
following severe sepsis will reveal the locations of DC generation.  
            Our observation of a gradual restoration of DC numbers after severe sepsis 
indicates that sepsis-induced DC depletion may not be the only mechanism responsible 
for the long-term immunosuppression and that DC functionality can also be altered after 
severe sepsis.  Our findings show that post-septic DCs exhibit a long-term impairment in 
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IL-12 expression, which subsequently compromises both the innate and adaptive immune 
response to a secondary pathological challenge.  Based on our studies, we propose that 
the long-term maintenance of DC alterations may be due to epigenetic regulation of 
expression patterns of key effector molecules.  Our data show that the long-term 
maintenance of aberrant gene expression is associated with epigenetic changes at Il12 
promoters in post-septic DCs, including histone acetylation and methylation at distinct 
lysine sites of histone proteins.  Furthermore, these epigenetic alterations are mediated by 
the altered recruitment of HMT complexes that specifically methylate individual lysine 
sites.  These observations led to the second question:  What are the key molecules/signals 
that mediate the epigenetic alterations in DCs post sepsis?  Recent data generated from 
experiments studying LPS-stimulated macrophages may shed some light on this question 
(205).  LPS-TLR4 signaling was shown to induce a short-term LPS unresponsiveness in 
macrophages, which was mediated by alterations in histone modifications.  This study 
indicated that TLR signaling is a potential contributor to epigenetic changes; however, 
signaling through TLR4 alone is not sufficient to build a long-term immune cell memory 
for the expression of certain genes.  In memory T cells, the candidate pathways leading to 
epigenetic alterations include T cell receptor and cytokine/cytokine receptor signaling 
pathways.  Based on the fact that an overwhelming pathological infection followed by a 
cytokine storm are the hallmarks of severe sepsis, it is reasonable to hypothesize that toll-
like receptor signaling and cytokine/cytokine receptor signaling pathways are potential 
contributors to the epigenetic changes.  It is also highly possible that synergy between 
individual TLR signaling pathways exists that results in downstream epigenetic changes, 
since synergy between different TLR signaling pathways has been shown to promote the 
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Th1-polarizing function of DCs (310).  Investigations of the role of the epigenetic 
alterations, including DNA methylation and histone modifications, in long-term DC 
dysfunction and immunosuppression following a severe acute inflammatory response will 
likely provide mechanistic insight into the longer-term sequela of sepsis and acute lung 
injury survivors.  These future studies will be important in laying the groundwork for the 
development of potentially novel cell and mediator-based therapeutic interventions. 
            Our data show that splenic DC dysfunction and epigenetic changes induced by 
severe sepsis persist for 6 weeks after the induction of peritonitis, by which time DC 
numbers have returned to normal levels.  This observation indicates that re-populated 
tissue DCs maintain aberrant cytokine production patterns, which are mediated, in part, 
by epigenetic changes.  The third remaining question is:  What is the mechanism leading 
to abnormal DC differentiation from precursor cells, given that epigenetic changes such 
as histone methylation are inherited during cell division (165, 311).  Further investigation 
is warranted to address the hypothesis that the intrinsic alterations in HSCs or precursor 
cells induced by severe sepsis lead to the generation of phenotypically altered DCs.  
Alternatively, severe sepsis might generate a long-lasting aberrant BM niche, which may 
continuously compromise normal DC differentiation.  Still another possibility is that after 
the acute episode of severe sepsis, the microenvironment in peripheral organs is 
permanently altered by the presence of abnormal structural cells or non-self antigens, 
which subsequently alter the phenotype of newly recruited DC.  To address this question, 
cross-transfer of sham or CLP BM cells into irradiated sham or CLP recipients followed 
by the investigation of peripheral DC phenotype will be performed.  Co-transfer of 
CD45.1+ sham and CD45.2+ CLP BM cells of equal number into an irradiated naïve 
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mouse followed by functional comparasion between peripheral CD45.1+ and CD45.2+ 
DC will further indicate whether severe sepsis-induced intrinsic alterations of HSCs is 
responsible for long-term maintenance of altered DC phenotype.  
    
Figure 6.1 Schematic of the long-term consequences of severe sepsis on the host's 
immune status.  There is a depletion of immune cells in the distal tissues and reduction 
of bone marrow cell populations.  When the tissues are re-seeded from the bone marrow 
profound changes have occurred, some induced by epigenetic alterations, which render 
the immune cells (DCs) unable to function normally in host responses and immune 
surveillance.        
 
            Figure 6.1 outlines our evolving hypothesis of the cellular and molecular 
mechanism by which an initial overwhelming innate immune response leads to a long-
term immunosuppressive state, such that the affected host loses the immune capacity to 
mount an appropriate defense response against a secondary pathological challenge.  
Severe sepsis results in a rapid depletion of immune cells such as DCs and T cells due to 
massive apoptosis at the early stage of this disorder; meanwhile, the subsequent 
repopulation of DCs, presumably through enhanced DC differentiation and proliferation 
from precursor cells has been initiated.  Although DC numbers can return to pre-septic 
levels after a long-term recovery, the newly generated BM-derived DCs are 
phenotypically altered, including aberrant cytokine expression pattern and APC function, 
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which are associated in part with epigenetic changes.  The long-term maintenance of 
dysfunctional DCs in peripheral tissue sites appears to compromise the host defense to a 
secondary pathological challenge.  The key aspects of this hypothesis include long-term 
abnormal DC differentiation from precursor cells and the maintenance of DC dysfunction 
mediated by an epigenetic mechanism, which can profoundly control the transcription of 
immune-specific genes.  Given that transplantation of DCs that have been manipulated in 
vitro, such as by challenge with tumor antigen, has become a successful strategy in 
cancer therapy (312-314), transplantation of immuno-competent DCs to patients who 
survive severe sepsis is a potential therapeutic strategy to rescue sepsis-associated 
immunosuppression.  The broader window of treatment timing of this approach bestows 
potential clinical benefits when compared to treatments aimed at the acute phase of sepsis 
during which time transition from SIRS to CARS occurs so rapidly that treatment 
strategies often fail (9, 17).  Although chemical manipulation of histone modifications is 
not yet available, this approach may present a future therapeutic strategy to reverse the 
long-term epigenetic changes induced by severe sepsis.  Collectively, our studies 
assessing novel mechanisms that dictate the long-lived immunosuppression associated 
with severe sepsis survivors provide insight into the development of new therapeutic 
strategies for an under-studied syndrome with significant clinical and financial 
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